

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/038281 A1

(43) International Publication Date
24 February 2022 (24.02.2022)

(51) International Patent Classification:

C07K 14/47 (2006.01) A61K 9/19 (2006.01)
A61K 38/17 (2006.01) A61K 47/02 (2006.01)
A61K 47/26 (2006.01) A61K 9/00 (2006.01)
A61K 47/10 (2017.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2021/073186

(22) International Filing Date:

20 August 2021 (20.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

20192142.6 21 August 2020 (21.08.2020) EP

(71) Applicant: **RESOTHER PHARMA APS** [DK/DK]; c/o "Næsseslottet" Dronninggårds Allé 136, 2840 Holte (DK).

(72) Inventors: **BUKRINSKI, Jens Thostrup**; Saxhøjvej 39A, 2500 Valby (DK). **TUELUNG, Pernille Sønderby**; Nordre Fasanvej 5 st th, 2000 Frederiksberg (DK). **JENSEN, Mette Hamborg**; Gedevassevej 17, 3520 Farum (DK).

(74) Agent: **HØIBERG P/S**; Adelgade 12, 1304 Copenhagen K (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- of inventorship (Rule 4.17(iv))

(54) Title: ANNEXIN A1 N-TERMINAL PEPTIDE FORMULATIONS AND METHODS

(57) Abstract: The present invention relates to pharmaceutical formulations comprising a therapeutically effective amount of an Annexin A1 (AnxA1) N-terminal-peptide having improved solubility and/or stability, while retaining agonistic activity at one or more of the formyl peptide receptors, including FPR1, FPR2 and FPR3.5



WO 2022/038281 A1

Annexin A1 N-terminal peptide formulations and methods

Technical field

The present invention relates to pharmaceutical formulations comprising an Annexin A1 (AnxA1) N-terminal-peptide with improved solubility and/or stability, including liquid formulations; freeze-dried formulations derived therefrom, as well as reconstituted formulations or solutions. The liquid formulations have a pH > 6, or 2 < pH < 3, and comprises a therapeutically effective amount of an Annexin A1 (AnxA1) N-terminal-peptide and a solvent selected from the group consisting of water, such as ultrapure water; and an essentially non-ionic or low-ionic, and/or essentially isotonic, solution, optionally comprising an isotonicity modifier, such as a carbohydrate and/or a sugar alcohol. The disclosed formulations are particularly effective for use in the treatment of ischemic and inflammatory conditions.

Background

The Annexin super-family consists of 13 calcium phospholipid binding proteins with significant biological and structural homology. Annexins are structurally divided into a highly conserved core domain and a variable N-terminal domain. Annexin A1 (ANXA1, 37 kDa – SEQ ID NO:1) is an anti-inflammatory protein that inhibits extravasation of blood-borne polymorphonuclear leukocyte (PMN) into the surrounding tissue. The protein binds to the N-formyl peptide receptor (FPR) 2 or FPR-L1 receptor, where it initiates a cascade of signaling events. Following an inflammatory stimulus, migration of blood-borne polymorphonuclear leukocyte (PMN) into the surrounding tissue takes place. Transmigration or extravasation of PMN is regulated by mediators such as adhesion molecules, cytokines and proteases, which control the pro-inflammatory and anti-inflammatory processes. The disruptive potential of the PMN is high and potentially self-damaging. Thus, controlling extravasation of PMN and the inflammatory response is important.

For therapeutic purposes as an anti-inflammatory agent, the full Annexin A1 protein has numerous disadvantages relative to functional fragments or modified versions thereof. The large size of the protein makes it more difficult to deliver by techniques that are possible with a smaller polypeptide (e.g. transdermally or transmucosally). For use to treat inflammation of the eyes, a smaller molecule is expected to be better able to penetrate the corneal epithelium. Also, susceptibility to proteolytic degradation is a

particular concern for all peptide pharmaceuticals, especially large ones and especially if oral delivery (preferred by many patients) is contemplated.

5 Some Annexin A1 derivatives lacking significant regions on the N-terminal side of the polypeptide have been shown to lack significant activity in some assays of inflammation and mediator release, whereas the full length N-terminus N-acetyl Annexin A1 was deemed biologically active in several systems. A number of peptides primarily derived from the unique N-terminal portion of the Annexin A1 protein have been shown to possess anti-inflammatory properties. One of the most extensively
10 studied Annexin A1 peptides is peptide Ac2-26, which mimics the 2nd to the 26th amino acids of the 54-amino acid N-terminal region. Like the Ac 1-188 fragment (and the native protein), it has an N-terminal acetylation to increase its stability, and possibly its half-life. It has been show that Annexin A1 and its N-terminal peptide (Ac2-26) exert the majority of their anti-inflammatory action through the FPR2/Lipoxin A4 (FPR2/AIx)
15 receptor. In vivo the Ac2-26 peptide has been shown to exert an anti-inflammatory effect in models of myocardial ischaemia reperfusion (I/R), mesentery I/R, glycogen peritonitis and IL1 airpouch, where it was reported to significantly reduce the recruitment of neutrophils to the site of injury/inflammation.

20 Shorter versions of the Ac2-26 peptide, such as peptides Ac2-12 and Ac2-6, have also been shown to elicit some degree of anti-inflammatory effects in acute models of inflammation. Longer polypeptides with anti-inflammatory effects, such as polypeptides corresponding to amino acid residues 2-48, 2-50 and 11-48, have been disclosed, including protease-resistant V24L variants (WO 2012/174397).

25 Peptide therapeutics have the potential to self-associate, leading to aggregation and/or fibrillation. To prepare stable peptide formulations the native peptide conformation should be maintained. Stable formulations and long-term stability are important in the development of effective therapeutic compositions that retains bioavailability, and
30 which can be used in delivery devices that expose the peptide to mechanical stress (e.g. continuous infusion systems).

The solubility of peptides in aqueous solutions is highly dependent on a number of factors including choice of buffering systems, tonicity provider and the concentration
35 and form of the peptide (e.g. salts and other modifications).

Given the therapeutic potential of Annexin A1 (AnxA1) N-terminal-peptides there is a need for developing safe, effective and stable formulations that can be administered by various routes of administration.

5

Summary

Annexin A1 (AnxA1) N-terminal-peptides, such as Annexin A1 2-48 V24L (SED ID NO:8) are shown herein to be poorly soluble with a very high fibrillation propensity in saline at neutral pH around 7,3 and as such not suitable for pharmaceutical administration. To overcome problems with solubility and stability the present inventors have developed stable solutions of Annexin A1 N-terminal-peptides, which reduce the propensity to form fibrils and particles, and preserve the peptide during optional freeze-drying to render it stable during storage of same.

15 The present disclosure relates to the finding that Annexin A1 N-terminal-peptides display a clear pH-dependent fibrillation profile, being completely insoluble at pH 6 and below in any solvent tested (saline, ultrapure water and essentially non-ionic and isotonic solutions). Hence maintaining a pH above 6 or below 3; such as above 6,5 or below 2,5; and in some embodiments maintaining an essentially non-ionic or low ionic strength (e.g. 1 uM to 50 mM) solution, such as by avoiding the presence of salts including saline; and optionally maintaining an essentially isotonic solution; markedly and unexpectedly increases solubility and stability of said Annexin A1 N-terminal-peptides.

25 The pharmaceutical formulations disclosed herein with improved solubility and/or stability comprise a therapeutically effective amount of an Annexin A1 N-terminal-peptide and a solvent selected from the group consisting of water, such as ultrapure water; and an essentially non-ionic or low-ionic, and/or essentially isotonic solution, said solution optionally comprising an isotonicity modifier, such as a carbohydrate and/or a sugar alcohol, wherein said formulations maintains a pH > 6, or 2 < pH < 3.

30

The pharmaceutical formulations are particularly useful in the treatment of ischemic and inflammatory conditions.

It is an aspect of the present disclosure to provide a liquid pharmaceutical formulation of pH > 6; or $2 < \text{pH} < 3$; said formulation comprising

- 5 a. a therapeutically effective amount of an Annexin A1 (AnxA1) N-terminal-peptide selected from the group consisting of
AMVSEFLKQ AWFIEENEEQE YVQTVKSSKG GPGSAVSPYP
TFNPSSDVAA LHKA (AnxA1 2-54; SEQ ID NO:3),
and a fragment thereof, and a variant thereof, and a variant of a
fragment thereof; and
- 10 b. a solvent selected from the group consisting of
- i. water, such as ultrapure water; and
- ii. an essentially non-ionic or low-ionic, and/or essentially isotonic,
solution,
optionally comprising an isotonicity modifier, such as a
carbohydrate and/or a sugar alcohol.

15

In one embodiment said Annexin A1 N-terminal-peptide is selected from the group consisting of:

- AMVSEFLKQAWFIEENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDVAA (SEQ ID
NO:4; Annexin A1 2-50),
- 20 AMVSEFLKQAWFIEENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDV (SEQ ID
NO:5; Annexin A1 2-48), and
AMVSEFLKQAWFIEENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSS (SEQ ID NO:6;
Annexin A1 2-46),
and a variant of any one of SEQ ID NOs:4-6, including variants having a V24L
25 substitution and C-terminal amidation.

It is also an aspect of the present disclosure to provide a lyophilized pharmaceutical formulation obtained by lyophilizing the liquid pharmaceutical formulation as disclosed herein. Also disclosed is a reconstituted solution of said lyophilized pharmaceutical
30 formulation. Also disclosed is the liquid pharmaceutical formulation, and a reconstituted solution of said lyophilized pharmaceutical formulation, as disclosed herein for use as a medicament, such as for use in the treatment of an ischemic condition and/or an inflammatory condition.

Description of Drawings

Figure 1: Results from the ThT assay indicating a reverse relationship between concentration and stability from the increase in lag-time when concentration is lower. It is seen that at 6.4 mg/mL, possibly 5.0 mg/ml, and above, the sample is already degraded by the formation of fibrils at time zero.

Figure 2: Photo of 5 mg/mL AnxA1 in Milli Q[®] water, 0.9% NaCl (154 mM) at pH=8; pH=6; pH=4 and; pH=2. All solutions are opaque indicating limited solubility of AnxA1

Figure 3: Concentration (A280) as a function of pH for 3 peptide concentrations. Three samples of AnxA1 was prepared at pH 9 in MilliQ[®] water, 0.9 % NaCl (154 mM) at concentrations 3.3, 1.6 and 0.8 mg/mL. pH was adjusted by addition of 0.1 M NaOH and the concentration determined using UV-VIS spectroscopy. It is clearly seen that below pH 6.0 solubility is very low.

Figure 4: Graphical representation of results presented in table 2 of Example 4.

Figure 5: Photograph of the visual appearance of samples containing AnxA1 at different pH values. A clear solution was observed ≥ 7.4 and from 2.6 – pH 2.0.

Figure 6: Photograph of visual appearance of solution in Milli Q[®] water with and without mannitol from pH 2 to 10. A clear solution is observed at pH 8 and 10, both with and without mannitol.

Figure 7: Graphical representation of the data presented in table 5 of Example 7.

Figure 8: AnxA1 purity in reconstituted solutions after up to 3 months storage of lyophilised formulation at 40°C, with measurements conducted at 0 months (T=0), 1 month (T=1), 2 months (T=2) and 3 months (T=3).

Figure 9: Graphical representation of lag times (hours) determined using the ThT assay for the formulations represented in table 9. No fibrillation is observed at pH 8.3 within analytical method (60 hours) independent of the tonicity provider, whereas at pH 7.5 the solution fibrillates after 35 hours. When comparing to the reference solution in PBS

and the formulation in saline (both at pH 7.4) it is also clear that using carbohydrates as tonicity providers is advantageous.

5 Figure 10: Contour plot of the experimental data from example 10. Illustrating the effect of pH, AnxA1 concentration and concentration of glycyl-glycine on lag time in the ThT assay (indicated by the numbers in the white boxes and with darker colours indicating longer lag-times). From the contour plot it is seen that physical stability (long lag-time) is dependent on i.a. low concentration of glycyl-glycine, low concentration of AnxA1 and high pH.

10

Figure 11: Contour plot of the experimental data from example 10. Illustrating the effect of pH, AnxA1 concentration and concentration of glycyl-glycine on lag time in the ThT assay (indicated by the numbers in the white boxes and with darker colours indicating longer lag-times). From the contour plot it is seen that the physical stability (long lag-time) is dependent on i.a. low concentration of glycyl-glycine, low concentration of AnxA1 and high pH.

15

Definitions

20 The singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

The term "subject" or "individual" for purposes of treatment includes any subject, and preferably is a subject who is in need of treatment of an ischemic and inflammatory condition. The subject is typically an animal, more typically a mammal. Preferably, the mammal is a human.

25

A "therapeutically effective amount" refers to an amount of an Annexin A1 N-terminal-peptide that is nontoxic but sufficient in treating, preventing or ameliorating the severity of an ischemic and inflammatory condition.

30

As used herein, "percent," "percentage" or the symbol "%" means the percent of the component indicated in the composition based on the amount of the carrier present in the composition, on a weight/weight (w/w), weight/volume (w/v) or volume/volume (v/v) concentration, as indicated with respect to any particular component, all based on the amount of the carrier present in the composition. Thus, different types of carriers can

35

be present in an amount of up to 100% as indicated, which does not preclude the presence of the API, the amount of which can be indicated as a % or as a certain number of mg present in the composition or a certain number of mg/mL present, where the % or mg/mL is based on the amount of the total carrier present in the composition.

5 Certain types of carriers can be present in combination to make up 100% of the carrier.

A "pharmaceutically acceptable carrier" as used herein is non-toxic or has certain toxic attributes that are not dose limiting to achieve therapeutic advantages to recipients at the dosages and concentrations required and is compatible with other ingredients of
10 the formulation.

The term "pharmaceutically acceptable excipient," includes vehicles, adjuvants, or diluents or other auxiliary substances, such as those conventional in the art, which are readily available to the public, and which are non-toxic or have acceptable toxicities to
15 recipients at the dosages and concentrations employed, and is compatible with other ingredients of the formulation. For example, pharmaceutically acceptable auxiliary substances include pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, anti-oxidants, preservatives, solubilizes, wetting agents and the like.

20 The term "pharmaceutical composition" or "pharmaceutical formulation" is intended to encompass a drug product including the active ingredient(s), pharmaceutically acceptable excipients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients. Accordingly, the pharmaceutical compositions of the present
25 disclosure encompass any composition made by admixing the active ingredient, active ingredient dispersion or composite, additional active ingredient(s), and pharmaceutically acceptable excipients.

Detailed description

30 Annexin A1 N-terminal-peptides, such as Annexin A1 2-48 V24L (SED ID NO:8) are poorly soluble in saline at neutral pH around 7,3 and as such not suitable for pharmaceutical administration.

35 On the basis of that, there is a need for developing safe, effective and stable formulations that can be administered by various routes of administration. The

formulations according to the present disclosure are provided in the form of a liquid pharmaceutical formulation which are stable and also suitable for freeze-drying, and as a water-soluble freeze-dried pharmaceutical formulation, that may be able to be stored for a satisfactorily long period of time prior to use. The water-soluble freeze-dried pharmaceutical formulation is intended for reconstitution to obtain a reconstituted solution prior to use.

Liquid formulation

It is an aspect to provide a liquid formulation, such as a liquid pharmaceutical formulation, of $\text{pH} > 6$; or $2 < \text{pH} < 3$, said formulation comprising

- a. an Annexin A1 (AnxA1) N-terminal-peptide, such as a therapeutically effective amount of an Annexin A1 (AnxA1) N-terminal-peptide, selected from the group consisting of
AMVSEFLKQ AWFIEENEEQE YVQTVKSSKG GPGSAVSPYP TFNPSSDVAA
LHKA (AnxA1 2-54; SEQ ID NO:3),
and a fragment thereof, and a variant thereof, and a variant of a fragment thereof;
and
- b. a solvent selected from the group consisting of
 - i. water, such as ultrapure water; and
 - ii. an essentially non-ionic or low-ionic, and/or essentially isotonic, solution, optionally comprising an isotonicity modifier.

In one embodiment said essentially non-ionic or low-ionic, and/or essentially isotonic, solution comprises an isotonicity modifier, such as a carbohydrate and/or a sugar alcohol.

An 'isotonicity modifier' is an agent that is added to adjust the tonicity of a solution.

In one embodiment the liquid pharmaceutical formulation according to the present disclosure has improved physical stability.

In one embodiment the liquid pharmaceutical formulation comprising an Annexin A1 N-terminal-peptide according to the present disclosure has improved solubility and/or reduced insolubility.

35

In one embodiment said liquid pharmaceutical formulation comprising an Annexin A1 N-terminal-peptide according to the present disclosure has reduced tendency to form fibrils, such as does not form fibrils.

- 5 In one embodiment the liquid pharmaceutical formulation according to the present disclosure comprises essentially no fibrils.

10 In one embodiment the liquid pharmaceutical formulation according to the present disclosure has low fibrillation propensity. In one embodiment the liquid pharmaceutical formulation according to the present disclosure has a low probability of forming fibrils. In one embodiment the liquid pharmaceutical formulation according to the present disclosure has a low probability of forming fibrils upon storage.

- 15 In one embodiment the liquid pharmaceutical formulation according to the present disclosure comprises essentially no visible particles.

In one embodiment the liquid pharmaceutical formulation according to the present disclosure comprises essentially no visible and/or subvisible particles.

- 20 In one embodiment the liquid pharmaceutical formulation according to the present disclosure comprises essentially no visible and/or subvisible proteinaceous particles.

25 Subvisible particles are usually defined as being in the size range 0.1 μm to 100 μm , often above the upper size limit for measurement by size-exclusion chromatography but not sufficiently large to be readily detectable by eye. Such particles may be proteinaceous (aggregates or proteins adsorbed onto other contaminants).

In one embodiment the liquid pharmaceutical formulation according to the present disclosure comprises essentially no proteinaceous particles of $\geq 0,1 \mu\text{m}$.

- 30 In one embodiment the liquid pharmaceutical formulation according to the present disclosure comprises essentially no proteinaceous particles of $\geq 1 \mu\text{m}$.

In one embodiment the liquid pharmaceutical formulation according to the present disclosure comprises essentially no proteinaceous particles of $\geq 10 \mu\text{m}$.

- 35 In one embodiment the liquid pharmaceutical formulation according to the present disclosure comprises essentially no proteinaceous particles of $\geq 100 \mu\text{m}$.

In one embodiment the lyophilised pharmaceutical formulation according to the present disclosure has improved chemical stability. In one embodiment the lyophilised pharmaceutical formulation according to the present disclosure has improved purity,
5 such as reduced impurity, such as improved content.

In one embodiment the liquid pharmaceutical formulation comprising an Annexin A1 N-terminal-peptide according to the present disclosure has

- a. improved physical stability,
- 10 b. improved solubility and/or reduced insolubility,
- c. reduced tendency to form fibrils,
- d. improved chemical stability, and/or
- e. improved purity, and/or reduced impurity, and/or improved content,

as compared to a liquid pharmaceutical formulation with a pH of $3 < \text{pH} < 6$, such as $3 < \text{pH} < 6,5$, such as $3 < \text{pH} < 7$, such as $3 < \text{pH} < 7,4$; and/or
15 as compared to a saline liquid pharmaceutical formulation; and/or
as compared to a solution having an ionic strength of $> 50 \text{ mM}$; and/or
as compared to a solution without an isotonicity modifier.

20 A solution is a homogeneous mixture composed of two or more substances. In such a mixture, a solute is a substance (such as a peptide) dissolved in another substance, known as a solvent.

pH is defined as the decimal logarithm of the reciprocal of the hydrogen ion activity, a_{H^+} , in a solution. Typically, the pH of solutions will change as temperature changes.
25 Hence, in one embodiment, reference herein to a certain pH value is meant to indicate a pH value at room temperature and/or ambient temperature. Ambient temperature is a term which refers to the actual temperature of the air (or other medium and surroundings) in any particular place, as measured by a thermometer, or the
30 temperature which surrounds an object. In a particular embodiment pH is measured at approx. 25 degree Celsius.

Maintaining pH at the prescribed level plays an important role in the stability of the Annexin A1 N-terminal peptides in solution. Specifically, maintaining a pH above 6; or $2 < \text{pH} < 3$; is essential in avoiding fibrillation (decreased physical stability), and the
35

inventors have found that maintaining the pH of the pharmaceutical formulation at around 7 to 9, such as 8 – 8,5, for example around 8,3 is advantageous in some embodiments. Typical peptide formulations have a more neutral pH of around 7 – 7,8, or even an acidic pH.

5

pH

In one embodiment the liquid pharmaceutical formulation of the present disclosure has a $\text{pH} > 6$; or $2 < \text{pH} < 3$; at room temperature. In one embodiment said liquid pharmaceutical formulation has a $\text{pH} > 6$; or $2 < \text{pH} < 3$; at ambient temperature. In one
10 embodiment said liquid pharmaceutical formulation has a $\text{pH} > 6$; or $2 < \text{pH} < 3$; at around 25°C.

In one embodiment the pH of the liquid pharmaceutical formulation is $\text{pH} \geq 6,5$.

15 In one embodiment the pH of the liquid pharmaceutical formulation is $\text{pH} \geq 6,5$, such as $\text{pH} \geq 7,0$, such as $\text{pH} \geq 7,5$, such as $\text{pH} \geq 8,0$. In one embodiment the pH of the liquid pharmaceutical formulation is $\text{pH} \geq 7,4$.

20 In one embodiment the pH of the liquid pharmaceutical formulation is $\text{pH} \geq 7,4$, such as $\text{pH} \geq 7,5$, such as $\text{pH} \geq 7,6$, such as $\text{pH} \geq 7,7$, such as $\text{pH} \geq 7,8$, such as $\text{pH} \geq 7,9$, such as $\text{pH} \geq 8,0$.

25 In one embodiment the pH of the liquid pharmaceutical formulation is $\text{pH} \leq 12$, such as $\text{pH} \leq 11,5$, such as $\text{pH} \leq 11$, such as $\text{pH} \leq 10,5$, such as $\text{pH} \leq 10$, such as $\text{pH} \leq 9,5$, such as $\text{pH} \leq 9$, such as $\text{pH} \leq 8,5$.

30 In one embodiment the pH of the liquid pharmaceutical formulation is $6 > \text{pH} \leq 6,5$, such as $6,5 \geq \text{pH} \leq 7$, such as $7 \geq \text{pH} \leq 7,5$, such as $7,5 \geq \text{pH} \leq 8$, such as $8 \geq \text{pH} \leq 8,5$, such as $8,5 \geq \text{pH} \leq 9$, such as $9 \geq \text{pH} \leq 9,5$, such as $9,5 \geq \text{pH} \leq 10$, such as $10 \geq \text{pH} \leq 10,5$, such as $10,5 \geq \text{pH} \leq 11$, such as $11 \geq \text{pH} \leq 11,5$, such as $11,5 \geq \text{pH} \leq 12$.

In one embodiment the pH of the liquid pharmaceutical formulation is $7,0 \geq \text{pH} \leq 7,5$, such as $7,5 \geq \text{pH} \leq 8$, such as $8 \geq \text{pH} \leq 8,5$, such as $8,5 \geq \text{pH} \leq 9$, such as $9 \geq \text{pH} \leq 9,5$, such as $9,5 \geq \text{pH} \leq 10$, such as $10 \geq \text{pH} \leq 10,5$.

35

In one embodiment the pH of the liquid pharmaceutical formulation is $7,0 \geq \text{pH} \leq 7,5$, such as $7,5 \geq \text{pH} \leq 8$, such as $8 \geq \text{pH} \leq 8,5$, such as $8,5 \geq \text{pH} \leq 9$, such as $9 \geq \text{pH} \leq 9,5$.

5 In one embodiment the pH of the liquid pharmaceutical formulation is such as $7,5 \geq \text{pH} \leq 8$, such as $8 \geq \text{pH} \leq 8,5$, such as $8,5 \geq \text{pH} \leq 9$.

In one embodiment the pH of the liquid pharmaceutical formulation is $8 \geq \text{pH} \leq 8,5$, such as $8,5 \geq \text{pH} \leq 9$. In one embodiment the pH of the liquid pharmaceutical formulation is $8 \geq \text{pH} \leq 8,5$.

10

In one embodiment the pH of the liquid pharmaceutical formulation is (approximately) 7,4, such as 7,5, such as 7,6, such as 7,7, such as 7,8, such as 7,9, such as 8,0, such as 8,1, such as 8,2, such as 8,3, such as 8,3, such as 8,4, such as 8,5, such as 8,6, such as 8,7, such as 8,8, such as 8,9, such as 9,0.

15

In one embodiment the pH of the liquid pharmaceutical formulation is $8 \geq \text{pH} \leq 8,5$.

In one embodiment the pH of the liquid pharmaceutical formulation is approximately 8,3.

20

In one embodiment the pH of the liquid pharmaceutical formulation is $2 < \text{pH} < 3$.

In one embodiment the pH of the liquid pharmaceutical formulation is $2 < \text{pH} < 2,6$.

25

In one embodiment the pH of the liquid pharmaceutical formulation is $\text{pH} \leq 3,0$, such as $\text{pH} \leq 2,5$, such as pH of approx. 2,5.

In one embodiment the pH of the liquid pharmaceutical formulation is $\text{pH} \geq 8$; or $2 < \text{pH} < 2,6$.

30

Solubility / Concentration

In one embodiment the Annexin A1 N-terminal-peptide has an aqueous solubility at $\text{pH} > 6$, such as $\text{pH} \geq 6,5$, such as at $6 > \text{pH} \leq 6,5$, such as $6,5 \geq \text{pH} \leq 7$, such as $7 \geq \text{pH} \leq 7,5$, such as $7,5 \geq \text{pH} \leq 8$, such as $8 \geq \text{pH} \leq 8,5$, such as $8,5 \geq \text{pH} \leq 9$, such as $9 \geq \text{pH} \leq 9,5$, such as $9,5 \geq \text{pH} \leq 10$, of at least 1,0 mg/ml, such as of at least 1,5 mg/ml, such as

35

at least 2,0 mg/ml, such as at least 2,5 mg/ml, such as at least 3,0 mg/ml, such as at least 3,5 mg/ml, such as at least 4,0 mg/ml, such as at least 5,5 mg/ml, such as at least 5,0 mg/ml, such as at least 7,5 mg/ml, such as at least 10,0 mg/ml.

5 In one embodiment the Annexin A1 N-terminal-peptide has an aqueous solubility of at least 0,1 mg/ml, such as at least 0,5 mg/ml, 1,0 mg/ml, such as at least 1,5 mg/ml, such as at least 2,0 mg/ml, such as at least 2,5 mg/ml, such as at least 3,0 mg/ml, such as at least 3,5 mg/ml, such as at least 4,0 mg/ml, such as at least 5,5 mg/ml, such as at least 5,0 mg/ml, such as at least 7,5 mg/ml, such as at least 10,0 mg/ml.

10

In one embodiment the Annexin A1 N-terminal-peptide has an aqueous solubility of at least 0,8 mg/ml, such as at least 1 mg/ml, such as at least 1,6, such as at least 2, such as at least 2,5, such as at least 3, such as at least 3,3, such as at least 3,5 mg/ml.

15

In one embodiment the liquid pharmaceutical formulation comprises said Annexin A1 N-terminal-peptide in a concentration of 0,1 to 50 mg/ml; such as in a concentration of 0,1 to 0,5 mg/ml, such as 0,5 to 1, such as 1 to 2, such as 2 to 3, such as 3 to 4, such as 4 to 5, such as 5 to 6, such as 6 to 7, such as 7 to 8, such as 8 to 9, such as 9 to 10, such as 10 to 11, such as 11 to 12, such as 12 to 13, such as 13 to 14, such as 14 to 20
20 15, such as 15 to 16, such as 16 to 17, such as 17 to 18, such as 18 to 19, such as 19 to 20 mg/ml, such as 20 to 21, such as 21 to 22, such as 22 to 23, such as 23 to 24, such as 24 to 25, such as 25 to 26, such as 26 to 27, such as 27 to 28, such as 28 to 29, such as 29 to 30 mg/ml, such as 30 to 31, such as 31 to 32, such as 32 to 33, such as 33 to 34, such as 34 to 35, such as 35 to 36, such as 36 to 37, such as 37 to 38,
25 such as 38 to 39, such as 39 to 40 mg/ml, such as 40 to 41, such as 41 to 42, such as 42 to 43, such as 43 to 44, such as 44 to 45, such as 45 to 46, such as 46 to 47, such as 47 to 48, such as 48 to 49, such as 49 to 50 mg/ml.

30

In one embodiment the liquid pharmaceutical formulation comprises said Annexin A1 N-terminal-peptide in a concentration of at least 0,1 mg/ml, such as at least 0,5 mg/ml, such as 1,0 mg/ml, such as at least 1,5 mg/ml, such as at least 2,0 mg/ml, such as at least 2,2 mg/ml, such as at least 2,5 mg/ml, such as at least 3,0 mg/ml, such as at least 3,5 mg/ml, such as at least 4,0 mg/ml, such as at least 4,5 mg/ml, such as at least 5,0 mg/ml.

35

In one embodiment the liquid pharmaceutical formulation comprises said Annexin A1 N-terminal-peptide in a concentration of at least 0,8 mg/ml, such as at least 1 mg/ml, such as at least 1,6, such as at least 2, such as at least 2,5, such as at least 3, such as at least 3,3, such as at least 3,5 mg/ml.

5

In one embodiment the liquid pharmaceutical formulation has a pH >6 and the Annexin A1 N-terminal-peptide has an aqueous solubility of at least 0,8 mg/ml, such as at least 1 mg/ml, such as at least 1,6, such as at least 2, such as at least 2,5, such as at least 3, such as at least 3,3, such as at least 3,5 mg/ml; and/or said formulation has a concentration of said Annexin A1 N-terminal-peptide of at least 0,8 mg/ml, such as at least 1 mg/ml, such as at least 1,6, such as at least 2, such as at least 2,5, such as at least 3, such as at least 3,3, such as at least 3,5 mg/ml

10

In one embodiment the liquid pharmaceutical formulation has a pH $\geq 7,4$, such as pH $\geq 8,0$, such as $\geq 8,3$, and the Annexin A1 N-terminal-peptide has an aqueous solubility of at least 4,0 mg/ml, such as at least 4,5 mg/ml, such as at least 5,0 mg/ml, such as at least 6,0 mg/ml, such as at least 7,0 mg/ml, such as at least 8,0 mg/ml, such as at least 9,0 mg/ml, such as at least 10,0 mg/ml, such as at least 15,0 mg/ml; and/or said formulation having a concentration of said Annexin A1 N-terminal-peptide of at least 4,0 mg/ml, such as at least 4,5 mg/ml, such as at least 5,0 mg/ml, such as at least 6,0 mg/ml, such as at least 7,0 mg/ml, such as at least 8,0 mg/ml, such as at least 9,0 mg/ml, such as at least 10,0 mg/ml, such as at least 15,0 mg/ml.

15

20

Solvent

The liquid pharmaceutical formulation comprises a solvent. In one embodiment said solvent is water, such as ultrapure water.

25

Ultrapure water (UPW), high-purity water or highly purified water (HPW) is water that has been purified to stringent specifications, and has the highest levels of purity for all contaminant types, including: organic and inorganic compounds; dissolved and particulate matter; volatile and non-volatile, reactive and inert; hydrophilic and hydrophobic; and dissolved gases.

30

The liquid pharmaceutical formulation comprises a solvent, which solvent preferably is not saline. In one embodiment the liquid pharmaceutical formulation comprises a non-saline solvent.

5 In a preferred embodiment the solvent comprise little or essentially no salts.

In one embodiment said solvent is **essentially non-ionic**, or low-ionic. In one embodiment said solvent has low-ionic strength. In one embodiment reference herein to 'essentially non-ionic' and 'low-ionic' is meant to refer to a solvent having low ionic
10 strength.

The ionic strength of a solution is a measure of the concentration of ions in that solution. Ionic compounds, when dissolved in water, dissociate into ions. One of the main characteristics of a solution with dissolved ions is the ionic strength. Ionic strength
15 can be molar (mol/L solution) or molal (mol/kg solvent). The molar ionic strength, I , of a solution is a function of the concentration of all ions present in that solution.

In one embodiment the solvent has an ionic strength of 1 μM to 50 mM.

20 In one embodiment the solvent has an ionic strength of 1 μM to 50 mM, such as 1 μM to 5 μM , such as 5 to 10 μM , such as 10 to 25 μM , such as 25 to 50 μM , such as 50 to 75 μM , such as 75 to 100 μM , such as 100 to 200 μM , such as 200 to 300 μM , such as 300 to 400 μM , such as 400 to 500 μM , such as 500 to 750 μM , such as 750 to 1000 μM (1 mM), such as 1 mM to 2 mM, such as 2 to 3 mM, such as 3 to 4 mM, such as 4
25 to 5 mM, such as 5 to 10 mM, such as 10 to 20 mM, such as 20 to 30 mM, such as 30 to 40 mM, such as 40 to 50 mM.

In one embodiment said solvent is an **essentially isotonic** solution. In one embodiment said solution has a tonicity of 100% +/- 100%. In one embodiment said
30 solvent is a solution having a tonicity of 100% +/- 100%.

Isotonicity means having equal tension; denoting solutions possessing the same osmotic pressure or tonicity; more specifically, limited to solutions in which eukaryotic cells neither swell nor shrink (no net flow of water across the semipermeable cell

membrane). Thus, a solution that is isosmotic with intracellular fluid will not be isotonic if it includes solute, such as urea, that freely permeates cell membranes.

5 An isotonic solution can be defined as having a tonicity of 100%, or approx. 300 mOsm.

10 In one embodiment said solution has a tonicity of approx. 100%, such as a tonicity of 100% +/- 100%, such as a tonicity of 0,1 % to 200 %; such as 80-85%, such as 85-90%, such as 90-95%, such as 95-100%, such as 100-105%, such as 105-110%, such as 110-115%, such as 115-120% tonicity.

15 In one embodiment said solution has a tonicity of 100% +/- 20%, such as a tonicity of 80% to 120%; such as 80-85%, such as 85-90%, such as 90-95%, such as 95-100%, such as 100-105%, such as 105-110%, such as 110-115%, such as 115-120% tonicity.

A tonicity of 100% +/- 20% is acceptable for regulatory purposes, while a tonicity of 100% +/- 100% is acceptable with justification.

20 In one embodiment said solution is 0-20% hypertonic, such as 0-5%, such as 5-10%, such as 10-15%, such as 15-20% hypertonic.

In one embodiment said solution is 0-20% hypotonic, such as 0-5%, such as 5-10%, such as 10-15%, such as 15-20% hypotonic.

25 In one embodiment said solvent comprises an **isotonicity modifier**. In one embodiment said solvent is a essentially isotonic solution comprising an isotonicity modifier.

30 In one embodiment said isotonicity modifier is selected from the group consisting of carbohydrates and sugar alcohols.

35 Sugar alcohols and carbohydrates share the same feature in their backbones, i. e., -CHOH-CHOH-. The sugar alcohols include such compounds as sorbitol, mannitol, glycerol, and polyethylene glycols (PEGs). These compounds are straight-chain molecules. The carbohydrates, such as sucrose, mannose, ribose, trehalose, maltose, glycerol, inositol, glucose and lactose, on the other hand, are cyclic molecules that may

contain a keto or aldehyde group. These two classes of compounds are effective in stabilizing protein against denaturation caused by elevated temperature and by freeze-thaw or freeze-drying processes.

- 5 In one embodiment said isotonicity modifier is selected from the group consisting of a carbohydrate, a sugar alcohol, and a combination of a carbohydrate and a sugar alcohol.

In one embodiment said solvent comprises a carbohydrate isotonicity modifier.

10

In one embodiment said solvent comprises a sugar alcohol isotonicity modifier.

In one embodiment said solvent comprises a carbohydrate and a sugar alcohol isotonicity modifier.

15

In one embodiment said sugar alcohol is not a liquid sugar alcohol, as these are not as useful for lyophilisation. In one embodiment said sugar alcohol is a solid sugar alcohol, such as a sugar alcohol which is solid at the conditions required for lyophilisation.

20

In one embodiment said isotonicity modifier is selected from the group consisting of pentose monosaccharides, hexose monosaccharides, disaccharides and trisaccharides.

25

In one embodiment said solution comprises one or more **pentose** monosaccharides (MW 150,13).

In one embodiment said solution comprises one or more pentose monosaccharides having a total weight percentage (w/v) of approx. 4.5% (isotonic).

30

In one embodiment said solution comprises one or more pentose monosaccharides having a total weight percentage (w/v) of 0,1 to 9%, such as 0,1 to 0,5, such as 0,5 to 1,0, such as 1,5 to 2,0, such as 1,5, to 2,0, such as 2,0 to 2,5, such as 2,5 to 3,0, such as 3,0 to 3,5, such as 3,5 to 4,0, such as 4,0 to 4,5, such as 4,5 to 5,0, such as 5,0 to 5,5, such as 5,5 to 6,0, such as 6,0 to 6,5, such as 7,0 to 7,5, such as 7,5 to 8,0, such as 8,0 to 8,5, such as 8,5 to 9,0% (w/v).

35

In one embodiment said solution comprises one or more pentose monosaccharides having a total weight percentage (w/v) of 3,6 to 5,4%; such as 3,6 to 3,8, such as 3,8 to 4,0, such as 4,0 to 4,2, such as 4,2 to 4,4, such as 4,4 to 4,6, such as 4,6 to 4,8, such as 4,8 to 5,0, such as 5,0 to 5,2% (w/v).

In one embodiment said solution comprises one or more **hexose** monosaccharides (MW 182,17).

10 In one embodiment said solution comprises one or more hexose monosaccharides having a total weight percentage (w/v) of approx. 5.5% (isotonic).

In one embodiment said solution comprises one or more hexose monosaccharides having a total weight percentage (w/v) of 0,1 to 10,9%, such as 0,1 to 0,5, such as 0,5 to 1,0, such as 1,5 to 2,0, such as 1,5, to 2,0, such as 2,0 to 2,5, such as 2,5 to 3,0, such as 3,0 to 3,5, such as 3,5 to 4,0, such as 4,0 to 4,5, such as 4,5 to 5,0, such as 5,0 to 5,5, such as 5,5 to 6,0, such as 6,0 to 6,5, such as 7,0 to 7,5, such as 7,5 to 8,0, such as 8,0 to 8,5, such as 8,5 to 9,0, such as 9,0 to 9,5, such as 9,5 to 10,0, such as 10,0 to 10,5, such as 10,5 to 10,9 % (w/v).

20 In one embodiment said solution comprises one or more hexose monosaccharides having a total weight percentage (w/v) of 4,4 to 6,6%, such as such as 4,4 to 4,6, such as 4,6 to 4,8, such as 4,8 to 5,0, such as 5,0 to 5,2, such as 5,2 to 5,4, such as 5,4 to 5,6, such as 5,6 to 5,8, such as 5,8 to 6,0, such as 6,0 to 6,2, such as 6,2 to 6,4, such as 6,4 to 6,6% (w/v).

In one embodiment said solution comprises one or more **disaccharides** (342,3).

30 In one embodiment said solution comprises one or more disaccharides having a total weight percentage (w/v) of approx. 10,3% (isotonic).

In one embodiment said solution comprises one or more disaccharides having a total weight percentage (w/v) of 0,1 to 20,5%, such as 0,1 to 1, such as 1-2, such as 2-3, such as 3-4, such as 4-5, such as 5-6, such as 6-7, such as 7-8, such as 8-9, such as 9-10, such as 10-11, such as 11-12, such as 12-13, such as 13-14, such as 14-15,

such as 15-16, such as 16-17, such as 17-18, such as 18-19, such as 19-20, such as 20-20,5% (w/v).

5 In one embodiment said solution comprises one or more disaccharides having a total weight percentage (w/v) of 8,2 to 12,3%, such as 8,2 to 8,5, such as 8,5 to 9, such as 9 to 9,5, such as 9,5 to 10, such as 10 to 10,5, such as 10,5 to 11, such as 11 to 11,5, such as 11,5 to 12, such as 12 to 12,3% (w/v).

10 In one embodiment said solution comprises one or more **trisaccharides** (MW 504,42).

In one embodiment said solution comprises one or more trisaccharides having a total weight percentage (w/v) of approx. 15,1% (isotonic).

15 In one embodiment said solution comprises one or more trisaccharides having a total weight percentage (w/v) of 0,1 to 30,3%, such as such as 0,1 to 1, such as 1-2, such as 2-3, such as 3-4, such as 4-5, such as 5-6, such as 6-7, such as 7-8, such as 8-9, such as 9-10, such as 10-11, such as 11-12, such as 12-13, such as 13-14, such as 14-15, such as 15-16, such as 16-17, such as 17-18, such as 18-19, such as 19-20, such as 20-21, such as 21-22, such as 22-23, such as 23-24, such as 24-25, such as 20 25-26, such as 26-27, such as 27-28, such as 28-29, such as 29-30, such as 30-30,3% (w/v).

25 In one embodiment said solution comprises one or more trisaccharides having a total weight percentage (w/v) of 12,1 to 18,2%, such as 12,1 to 12,5, such as 12,5 to 13, such as 13 to 13,5, such as 13,5 to 14, such as 14 to 14,5, such as 14,5-15, such as 15 to 15,5, such as 15,5 to 16, such as 16 to 16,5, such as 16,5 to 17, such as 17,5 to 18, such as 18 to 18,2% (w/v).

30 In one embodiment said carbohydrate isotonicity modifier is selected from the group consisting of: sucrose, trehalose, mannose, ribose, maltose, glucose, lactose, galactose and arabinose.

35 In one embodiment said sugar alcohol isotonicity modifier is selected from the group consisting of: mannitol, sorbitol, inositol, glycerol, xylitol, propylene glycol, polyethylene glycols (PEGs) and polypropylene/ethylene glycol copolymer.

In a particular embodiment said solution comprises sucrose or trehalose.

5 In a particular embodiment said solution comprises sucrose. Sucrose is shown herein to be efficient in providing chemical stability.

In one embodiment the solution comprises approx. 10% (w/v) sucrose.

In one embodiment the solution comprises 8-12% (w/v) sucrose, such as 8-9, such as 9-10, such as 10-11, such as 11-12% (w/v) sucrose.

In one embodiment the solution comprises approx. 1% (w/v) sucrose.

10 In one embodiment the solution comprises 1-5% (w/v) sucrose, such as 1-2, such as 2-3, such as 3-4, such as 4-5 (w/v) sucrose.

In one embodiment the solution comprises 0-20% (w/v) sucrose, such as 0,1-1, 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 8-9, 9-10, 10-11, 11-12, 12-13, 13-14, 14-15, 15-16, 16-17, 17-18, 18-19, 19-20% (w/v) sucrose.

In a particular embodiment said solution comprises mannitol.

In one embodiment the solvent comprises approx. 5% (w/v) mannitol.

20 In one embodiment the solution comprises 4-6% (w/v) mannitol, such as 4 to 6% (w/v) mannitol, such as 4 to 4,5, such as 4,5 to 5, such as 5 to 5,5, such as 5,5 to 6% mannitol.

In one embodiment the solvent comprises approx. 4% (w/v) mannitol.

25 In one embodiment the solution comprises 3-5% (w/v) mannitol, such as 3 to 5% (w/v) mannitol, such as 3 to 3,5, such as 3,5 to 4, such as 4 to 4,5, such as 4,5 to 4% mannitol.

In one embodiment the solution comprises 0-10% (w/v) mannitol, such as 0,1-1, such as 1-2, such as 2-3, such as 3-4, such as 4-5, such as 5-6, such as 6-7, such as 7-8, such as 8-9, such as 9-10% (w/v) mannitol.

30

In one embodiment said solution comprises mannitol, and sucrose or trehalose.

In one embodiment said solution comprises mannitol and sucrose.

In one embodiment the solution comprises 0-20% (w/v) sucrose, such as 0,1-1, 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 8-9, 9-10, 10-11, 11-12, 12-13, 13-14, 14-15, 15-16, 16-17, 17-18, 18-19, 19-20% (w/v) sucrose, and comprises 0-10% (w/v) mannitol, such as 0,1-1, such as 1-2, such as 2-3, such as 3-4, such as 4-5, such as 5-6, such as 6-7, such as 7-8, such as 8-9, such as 9-10% (w/v) mannitol.

In one embodiment said solution comprises approx. 4% (w/v) mannitol and approx. 2,5% sucrose.

In one embodiment said solution comprises 3 to 5% (w/v) mannitol and 2 to 3% (w/v) sucrose.

In one embodiment said solution comprises approx. 4% (w/v) mannitol and approx. 1% sucrose.

In one embodiment said solution comprises 3 to 5 % (w/v) mannitol and 0,5 to 2% sucrose.

In one embodiment said solution comprises 0 to 8 % (w/v) mannitol and 0 to 5% (w/v) sucrose. In one embodiment said solution comprises 0 to 8 % (w/v) mannitol, such as 0 to 1, such as 1 to 2, such as 2 to 3, such as 3 to 4, such as 4 to 5, such as 5 to 6, such as 6 to 7, such as 7 to 8% (w/v) mannitol; and 0 to 5% (w/v) sucrose, such as 0 to 1, such as 1 to 2, such as 2 to 3, such as 3 to 4, such as 4 to 5 (w/v) sucrose.

In a particular embodiment said isotonicity modifier preserves the peptide against chemical degradation during lyophilisation. It is observed that carbohydrates are well-suited for this purpose. In one embodiment the liquid pharmaceutical formulation comprises one or more carbohydrates, such as one or more carbohydrates that improve chemical stability, such as that preserve the peptide during lyophilisation.

In one embodiment the liquid pharmaceutical formulation comprises one or more carbohydrates selected from the group consisting of sucrose and trehalose. In one embodiment the liquid pharmaceutical formulation comprises sucrose.

Also disclosed is a liquid pharmaceutical formulation of $\text{pH} > 6$, or $2 < \text{pH} < 3$, said formulation comprising

- a. a therapeutically effective amount of an Annexin A1 (AnxA1) N-terminal-peptide selected from the group consisting of
5 AMVSEFLKQ AWFIEENEEQE YVQTVKSSKG GPGSAVSPYP
TFNPSSDVAA LHKA (AnxA1 2-54; SEQ ID NO:3),
and a fragment thereof, and a variant thereof, and a variant of a fragment thereof; and
- b. a solvent selected from the group consisting of
 - 10 i. water, such as ultrapure water; and
 - ii. an essentially non-ionic or low-ionic, and/or essentially isotonic, solution optinally comprising an isotonicity modifier, such as a carbohydrate and/or a sugar alcohol;and a buffer.

15

In one embodiment the liquid pharmaceutical formulation comprises one or more buffers, such as a buffer.

20 The choice of buffer can also affect stability of peptide formulations in part because the choice of buffer affects the pH. The buffers used in the present disclosure preferably provides a buffering capacity above 6, for example above 7, such as above 8. There are few pharmaceutically acceptable buffers in the alkaline range, and phosphate buffers typically used in peptide formulations cannot maintain a pH above 8.

25 In one embodiment said buffer aids in stabilizing the pH of the liquid formulation. pH is important for the physical stability of the AnxA1 N-terminal-peptide.

30 In one embodiment the liquid pharmaceutical formulation comprises one or more buffers selected from the group consisting of Acetate buffer, TRIS, Amine-containing buffers, Amino-acid based buffers such as lysine, hydroxy-lysine histidine and glycyl-glycine, non-phosphate buffers, bicarbonate buffers, Polysorbate-80 (e.g. Tween 80), HEPES and borate.

In one embodiment the liquid pharmaceutical formulation comprises glycyl-glycine.

35 In one embodiment the liquid pharmaceutical formulation comprises Tween20.

In one embodiment the liquid pharmaceutical formulation comprises glycyl-glycine and Tween20. In one embodiment the liquid pharmaceutical formulation comprises 1 to 20 mM glycyl-glycine and 0,001 to 0,1% Tween20. In one embodiment the liquid pharmaceutical formulation comprises 10mM glycyl-glycine and 0,01% Tween20.

5 In one embodiment the liquid pharmaceutical formulation comprises histidine.

In one embodiment the liquid pharmaceutical formulation further comprises a preservative. In one embodiment said preservative is selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl, propyl parabens, butyl parabens, methyl parabens, and phenol.

10

Preparing liquid formulation

It is also an aspect of the present disclosure to provide a process of preparing a liquid pharmaceutical formulation as defined herein above, said process comprising the steps of

15

- a. mixing an Annexin A1 N-terminal-peptide, as defined herein above, with a solvent selected from the group consisting of
 - i. water, such as ultrapure water; and
 - ii. an essentially non-ionic or low-ionic, and/or essentially isotonic, solution, optionally comprising an isotonicity modifier, such as a carbohydrate and/or a sugar alcohol,
 - b. optionally filtering the mixture of step a., and
 - c. adjusting the pH of said liquid pharmaceutical formulation to $\text{pH} < 6$; or $2 < \text{pH} < 3$.
- 20

In one embodiment the pH of said liquid pharmaceutical formulation is adjusted to $6 > \text{pH} \leq 6,5$, such as $6,5 \geq \text{pH} \leq 7$, such as $7 \geq \text{pH} \leq 7,5$, such as $7,5 \geq \text{pH} \leq 8$, such as $8 \geq \text{pH} \leq 8,5$, such as $8,5 \geq \text{pH} \leq 9$, such as $9 \geq \text{pH} \leq 9,5$, such as $9,5 \geq \text{pH} \leq 10$, such as $10 \geq \text{pH} \leq 10,5$, such as $10,5 \geq \text{pH} \leq 11$, such as $11 \geq \text{pH} \leq 11,5$, such as $11,5 \geq \text{pH} \leq 12$.

25

30

In one embodiment the pH of said liquid pharmaceutical formulation is adjusted to $\geq 7,4$. In one embodiment the pH of said liquid pharmaceutical formulation is adjusted to $\geq 7,5$, such as ≥ 8 , such as $\geq 8,5$, such as ≥ 9 .

35

In one embodiment the pH of said liquid pharmaceutical formulation is adjusted to $2 < \text{pH} < 3$, such as $\text{pH} \leq 3,0$, such as $\text{pH} \leq 2,5$, such as approx. pH of 2,5.

5 In one embodiment the process comprises mixing of said Annexin A1 N-terminal-peptide at a concentration of at least 0,1 mg/ml, such as at least 0,5 mg/ml, such as at least 1,0 mg/ml, such as at least 1,5 mg/ml, such as at least 2,0 mg/ml, such as at least 2,5 mg/ml, such as at least 3,0 mg/ml, such as at least 3,5 mg/ml, such as at least 4,0 mg/ml, such as at least 5,5 mg/ml, such as at least 5,0 mg/ml, such as at least 7,5 mg/ml, such as at least 10,0 mg/ml.

10

In one embodiment the process comprises mixing of said Annexin A1 N-terminal-peptide at a concentration of 0,1 to 50 mg/ml; such as in a concentration of 0,1 to 0,5 mg/ml, such as 0,5 to 1 mg/ml, such as 1 to 2 mg/ml, such as 2 to 3, such as 3 to 4, such as 4 to 5, such as 5 to 6, such as 6 to 7, such as 7 to 8, such as 8 to 9, such as 9
15 to 10, such as 10 to 11, such as 11 to 12, such as 12 to 13, such as 13 to 14, such as 14 to 15, such as 15 to 16, such as 16 to 17, such as 17 to 18, such as 18 to 19, such as 19 to 20 mg/ml, such as 20 to 21, such as 21 to 22, such as 22 to 23, such as 23 to 24, such as 24 to 25, such as 25 to 26, such as 26 to 27, such as 27 to 28, such as 28 to 29, such as 29 to 30 mg/ml, such as 30 to 31, such as 31 to 32, such as 32 to 33,
20 such as 33 to 34, such as 34 to 35, such as 35 to 36, such as 36 to 37, such as 37 to 38, such as 38 to 39, such as 39 to 40 mg/ml, such as 40 to 41, such as 41 to 42, such as 42 to 43, such as 43 to 44, such as 44 to 45, such as 45 to 46, such as 46 to 47, such as 47 to 48, such as 48 to 49, such as 49 to 50 mg/ml.

25 *Lyophilized formulation*

In one embodiment the liquid pharmaceutical formulation according to the present disclosure is lyophilised, or freeze-dried. Lyophilization is a water removal process typically used to preserve materials, to extend shelf life and/or make the material more convenient for transport. Lyophilization works by rapid freezing and dehydration of the
30 frozen product under high vacuum (low pressure).

In one embodiment the liquid pharmaceutical formulation according to the present disclosure is lyophilised.

In one embodiment there is provided a stable, such as shelf-stable, lyophilized pharmaceutical formulation, as disclosed herein.

5 In one embodiment the peptide is protected against chemical degradation during lyophilisation, to obtain a stable, such as a shelf-stable, lyophilized pharmaceutical formulation

It is an aspect of the present disclosure to provide a process of preparing a lyophilized pharmaceutical formulation, said method comprising the steps of

- 10 a. providing a liquid pharmaceutical formulation of $\text{pH} > 6$; or $2 < \text{pH} < 3$, said formulation comprising a therapeutically effective amount of an Annexin A1 N-terminal-peptide selected from the group consisting of AMVSEFLKQ AWFIEENEEQE YVQTVKSSKG GPGSAVSPYP TFNPSSDVAA LHKA (AnxA1 2-54; SEQ ID NO:3),
- 15 and a fragment thereof, and a variant thereof, and a variant of a fragment thereof; and a solvent selected from the group consisting of
- i. water, such as ultrapure water; and
 - ii. an essentially non-ionic or low-ionic, and/or essentially isotonic, solution, optionally comprising an isotonicity modifier, such as
- 20 a carbohydrate and/or a sugar alcohol;
- and optionally a buffer, and
- b. lyophilizing said liquid pharmaceutical formulation of step a.

25 In one embodiment there is provided a process of preparing a lyophilized pharmaceutical formulation, said method comprising the steps of

- a. freezing a liquid pharmaceutical formulation as defined herein above,
- b. primary drying (sublimation phase), comprising lowering pressure and heating, and
- c. secondary drying (desorption phase)

30

It is also an aspect of the present disclosure to provide a lyophilized pharmaceutical formulation obtained by the process of providing a liquid pharmaceutical formulation according to the present disclosure, and lyophilizing said liquid pharmaceutical formulation.

35

In one embodiment there is provided a lyophilized pharmaceutical formulation, said lyophilized pharmaceutical formulation being obtained by the process of

- 5 a. providing a liquid pharmaceutical formulation of $\text{pH} > 6$; or $2 < \text{pH} < 3$, said formulation comprising a therapeutically effective amount of an Annexin A1 N-terminal-peptide selected from the group consisting of AMVSEFLKQ AWFIEENEEQE YVQTVKSSKG GPGSAVSPYP TFNPSSDVAA LHKA (AnxA1 2-54; SEQ ID NO:3), and a fragment thereof, and a variant thereof, and a variant of a fragment thereof; and a solvent selected from the group consisting of
- 10 i. water, such as ultrapure water; and
- ii. an essentially non-ionic or low-ionic, and/or essentially isotonic, solution, optionally comprising an isotonicity modifier, such as a carbohydrate and/or a sugar alcohol; and optionally a buffer, and
- 15 b. lyophilizing said liquid pharmaceutical formulation of step a.

In one embodiment said lyophilized pharmaceutical formulation is stable, such as a shelf-stable, during storage.

Reconstituted liquid formulation / solution

- 20 It is a further aspect of the present disclosure to provide a method of making a reconstituted solution comprising an Annexin A1 N-terminal-peptide, said method comprising
- a. providing a lyophilized pharmaceutical formulation according to the present disclosure, and
- 25 b. dissolving said lyophilized pharmaceutical formulation in a solvent.

In one embodiment the resulting solution has a $\text{pH} > 6$; or $2 < \text{pH} < 3$. In one embodiment said solution has a pH of $6 > \text{pH} \leq 6,5$, such as $6,5 \geq \text{pH} \leq 7$, such as $7 \geq \text{pH} \leq 7,5$, such as $7,5 \geq \text{pH} \leq 8$, such as $8 \geq \text{pH} \leq 8,5$, such as $8,5 \geq \text{pH} \leq 9$, such as $9 \geq \text{pH} \leq 9,5$, such as $9,5 \geq \text{pH} \leq 10$, such as $10 \geq \text{pH} \leq 10,5$, such as $10,5 \geq \text{pH} \leq 11$, such as $11 \geq \text{pH} \leq 11,5$, such as $11,5 \geq \text{pH} \leq 12$. In one embodiment said solution has a pH of $2 < \text{pH} < 3$, such as $\text{pH} \leq 3,0$, such as $\text{pH} \leq 2,5$, such as pH of approx. 2,5.

30

In one embodiment said solvent is selected from the group consisting of

- 35 a. water, such as ultrapure water; and

- b. an essentially non-ionic or low-ionic, and/or essentially isotonic, solution optionally comprising an isotonicity modifier, such as a carbohydrate and/or a sugar alcohol.

5 In a particular embodiment said solvent is water, such as ultrapure water.

In one embodiment the solvent has a pH > 6; or $2 < \text{pH} < 3$. In one embodiment said solvent has a pH of $6 > \text{pH} \leq 6,5$, such as $6,5 \geq \text{pH} \leq 7$, such as $7 \geq \text{pH} \leq 7,5$, such as $7,5 \geq \text{pH} \leq 8$, such as $8 \geq \text{pH} \leq 8,5$, such as $8,5 \geq \text{pH} \leq 9$, such as $9 \geq \text{pH} \leq 9,5$, such as $9,5 \geq \text{pH} \leq 10$, such as $10 \geq \text{pH} \leq 10,5$, such as $10,5 \geq \text{pH} \leq 11$, such as $11 \geq \text{pH} \leq 11,5$, such as $11,5 \geq \text{pH} \leq 12$. In one embodiment said solvent has a pH of $2 < \text{pH} < 3$, such as $\text{pH} \leq 3,0$, such as $\text{pH} \leq 2,5$, such as pH of approx. 2,5.

15 Also disclosed is a reconstituted solution obtained by the method of making a reconstituted solution comprising an Annexin A1 N-terminal-peptide disclosed herein.

Annexin A1 N-terminal peptide

On the cell surface the Annexin A1 (AnxA1) protein is exposed to extracellular fluids and in the presence of calcium undergoes structural re-organization, consequent to interaction with phospholipids via the core region of the protein (~280 amino acid long), which leads to the exposure of the N-terminal region (~50 amino acid long). This conformational change is thought to lead to the interaction of the AnxA1 N-terminus with specific receptors. The N-terminus of AnxA1 comprises amino acids 1-54 (SEQ ID NO:2).

25 In addition to representing the pharmacophore of the protein affording interaction with counter-ligands, the N-terminus is also a highly regulated region. It can undergo phosphorylation on specific Tyrosine or Serine sites, a pre-requisite for secretion in certain cell types, or can be cleaved by serine proteases. A number of proteases have been shown to cleave at specific sites within the AnxA1 N-terminal region and it is plausible that this process is not an *in vitro* artifact but of biological significance.

35 Both human recombinant AnxA1 and the N-terminal peptide Ac2-26 exert anti-inflammatory and pro-resolving effects in a variety of experimental models.

A number of peptides primarily derived from the unique N-terminal portion of the Annexin A1 protein have been shown to possess anti-inflammatory properties.

5 An *Annexin A1 N-terminal-peptide* as defined herein is a peptide comprising or consisting of the amino acid sequence AMVSEFLKQ AWFIEENEEQE YVQTVKSSKG GPGSAVSPYP TFNPSSDVAA LHKA (AnxA1 2-54; SEQ ID NO:3), including any shorter fragments thereof, any variants thereof, as well as any variant of said shorter fragment thereof.

10 The present disclosure provides a liquid pharmaceutical formulation comprising a therapeutically effective amount of an Annexin A1 N-terminal-peptide selected from the group consisting of
AMVSEFLKQ AWFIEENEEQE YVQTVKSSKG GPGSAVSPYP TFNPSSDVAA LHKA
(AnxA1 2-54; SEQ ID NO:3),
15 and a fragment thereof, and a variant thereof, and a variant of a fragment thereof; and a solvent.

In one embodiment said Annexin A1 N-terminal-peptide is selected from the group consisting of
20 AMVSEFLKQ AWFIEENEEQE YVQTVKSSKG GPGSAVSPYP TFNPSSDVAA LHKA
(AnxA1 2-54; SEQ ID NO:3),
and a fragment of SEQ ID NO:3, wherein said fragment comprises 5 to 52 consecutive amino acids of SEQ ID NO:3, such as 5-10, such as 10-15, such as 15-20, such as 20-25, such as 25-30, such as 30-35, such as 35-40, such as 40-45, such as 45-50, such
25 as 50-53 consecutive amino acids of SEQ ID NO:3,
and a variant of SEQ ID NO:3, wherein said variant comprises 1 to 6 individual amino acid substitutions, such as 1 amino acid substitution, such as 2 amino acid substitutions, such as 3 amino acid substitutions, such as 4 amino acid substitutions, such as 5 amino acid substitutions, such as 6 individual amino acid substitutions.

30 In one embodiment said fragment of SEQ ID NO:3 comprises or consists of 5 or more consecutive amino acids of SEQ ID NO:3, such as comprises or consists of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52
35 consecutive amino acids of SEQ ID NO:3.

In one embodiment said Annexin A1 N-terminal-peptide is selected from the group consisting of:

AMVSEFLKQAWFIENEEQEYVQTVK (SED ID NO:10; Annexin A1 2-26),

5 and a variant of SEQ ID NO:10, wherein said variant comprises 1 to 6 individual amino acid substitutions, such as 1 amino acid substitution, such as 2 amino acid substitutions, such as 3 amino acid substitutions, such as 4 amino acid substitutions, such as 5 amino acid substitutions, such as 6 individual amino acid substitutions.

10 In one embodiment said Annexin A1 N-terminal-peptide is selected from the group consisting of:

AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDVAA (SED ID NO:4; Annexin A1 2-50),

15 AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDV (SED ID NO:5; Annexin A1 2-48), and

AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSS (SED ID NO:6; Annexin A1 2-46),

20 and a variant of any one of SEQ ID NOs:4-6, wherein said variant comprises 1 to 6 individual amino acid substitutions, such as 1 amino acid substitution, such as 2 amino acid substitutions, such as 3 amino acid substitutions, such as 4 amino acid substitutions, such as 5 amino acid substitutions, such as 6 individual amino acid substitutions.

25 In one embodiment said variant comprises 1 to 6 individual amino acid substitutions, such as 1 to 2 amino acid substitutions, such as 2 to 3 amino acid substitutions, such as 3 to 4 amino acid substitutions, such as 4 to 5 amino acid substitutions, such as 5 to 6 individual amino acid substitutions.

30 In one embodiment said one or more amino acid substitutions are conservative amino acid substitutions. In one embodiment said one or more amino acid substitutions are non-conservative amino acid substitutions.

A variant of a peptide as defined herewith can in principle have one or more substitutions at one or more positions. Individual amino acid residues in the disclosed

sequences can be substituted with any given proteinogenic or non-proteinogenic amino acid.

5 The genetic code specifies 20 standard amino acids naturally incorporated into polypeptides (proteinogenic): Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Tyr, Thr, Trp, Val, and 2 which are incorporated into proteins by unique synthetic mechanisms: Sec (selenocysteine, or U) and Pyl (pyrrolysine, O). These are all L-stereoisomers.

10 Aside from the 22 standard or natural amino acids, there are many other non-naturally occurring amino acids (non-proteinogenic or non-standard). They are either not found in proteins, or are not produced directly and in isolation by standard cellular machinery. Non-standard amino acids are usually formed through modifications to standard amino acids, such as post-translational modifications. Examples of unnatural amino acid
15 residues are Abu, Aib, Nle (Norleucine), DOrn (D-ornithine, deguanylated arginine), Nal (beta-2-naphthyl-alanine), D-Nal (beta-2-naphthyl-D-alanine), DArg, DTrp, DPhe and DVal.

20 Any amino acids according to the present disclosure may be in the L- or D-configuration. If nothing is specified, reference to the L-isomeric form is preferably meant.

The term polypeptide also embraces post-translational modifications introduced by chemical or enzyme-catalyzed reactions, as are known in the art. Such post-
25 translational modifications can be introduced prior to partitioning, if desired. Also, functional equivalents may comprise chemical modifications such as ubiquitination, labeling (e.g., with radionuclides, various enzymes, etc.), pegylation (derivatization with polyethylene glycol), or by insertion (or substitution by chemical synthesis) of amino acids, which do not normally occur in human proteins (e.g. ornithine).

30

Polypeptides as defined herein with N-terminal alkylations and C-terminal esterifications are also encompassed within the present disclosure. Functional equivalents also comprise glycosylated and covalent or aggregative conjugates formed with the same molecules, including dimers or unrelated chemical moieties. Such
35 functional equivalents are prepared by linkage of functionalities to groups which are

found in a fragment including at any one or both of the N- and C-termini, by means known in the art.

5 In one embodiment said Annexin A1 N-terminal-peptide comprises at least 1 amino acid substitution, wherein the valine (V) at position 24 of any one of SEQ ID NOs:3-6 and 10 is substituted with any other standard or non-standard amino acid.

10 In one embodiment said Annexin A1 N-terminal-peptide comprises at least 1 amino acid substitution, wherein the valine (V) at position 24 of any one of SEQ ID NOs:3-6 and 10 is substituted with an amino acid residue independently selected from the group consisting of glycine, alanine, serine, threonine, cysteine, leucine, isoleucine, methionine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, asparagine, glutamine, histidine, lysine and arginine.

15 In one embodiment said Annexin A1 N-terminal-peptide comprises at least 1 amino acid substitution, wherein the valine (V) at position 24 of any one of SEQ ID NOs:3-6 and 10 is substituted with leucine (L) (Val24Leu or V24L). In some embodiments the Val24Leu mutation increases protease stability.

20 In one embodiment said Annexin A1 N-terminal-peptide is selected from the group consisting of:
AMVSEFLKQAWFIENEEQEYVQTLK (SEQ ID NO:11; Annexin A1 2-26 V24L),
and a variant of SEQ ID NO:11, wherein said variant comprises 1 to 6 individual amino acid substitutions, such as 1 amino acid substitution, such as 2 amino acid
25 substitutions, such as 3 amino acid substitutions, such as 4 amino acid substitutions, such as 5 amino acid substitutions, such as 6 individual amino acid substitutions, such as wherein said variant comprises V24L.

30 In one embodiment said Annexin A1 N-terminal-peptide is selected from the group consisting of:
AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDVAA (SEQ ID NO:7; Annexin A1 2-50 V24L),
AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV (SEQ ID NO:8; Annexin A1 2-48 V24L), and

AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSS (SEQ ID NO:9; Annexin A1 2-46 V24L),

and a variant of any one of SEQ ID NOs:7-9, wherein said variant comprises 1 to 6 individual amino acid substitutions, such as 1 amino acid substitution, such as 2 amino acid substitutions, such as 3 amino acid substitutions, such as 4 amino acid substitutions, such as 5 amino acid substitutions, such as 6 individual amino acid substitutions; such as wherein said variant comprises V24L.

10 In one embodiment said one or more amino acid substitutions are conservative amino acid substitutions.

In one embodiment the alanine residue at position 10 of any one of SEQ ID NOs:3-11 is substituted with any other standard or non-standard amino acid.

15

In one embodiment the alanine residue at position 10 of any one of SEQ ID NOs:3-11 is substituted with an amino acid residue independently selected from the group consisting of leucine, aspartic acid, methionine, glutamic acid, isoleucine and arginine.

20 In one embodiment the amino acid residue at position 10 of any one of SEQ ID NOs:3-11 is not alanine; i.e. is any amino acid except for alanine.

In one embodiment the valine residue at position 21 of any one of SEQ ID NOs:3-11 is substituted with any other standard or non-standard amino acid.

25

In one embodiment the valine residue at position 21 of any one of SEQ ID NOs:3-11 is substituted with an amino acid residue independently selected from the group consisting of leucine, aspartic acid, methionine, glutamic acid, isoleucine and lysine.

30 In one embodiment the residue at position 21 of any one of SEQ ID NOs:3-11 is not valine, i.e. is any amino acid except for valine.

In one embodiment the alanine residue at position 10 and the valine residue at position 21 of any one of SEQ ID NOs:3-11 are both substituted with an amino acid residue independently selected from the group consisting of leucine, aspartic acid, methionine,

35

glutamic acid, isoleucine, arginine and lysine; such as the group consisting of leucine, aspartic acid and methionine; such as leucine. In one embodiment residue 10 and residue 21 of any one of SEQ ID NOs:3-11 are identical.

5 In one embodiment the valine residue at position 35 of any one of SEQ ID NOs:3-9 is substituted with any other standard or non-standard amino acid.

10 In one embodiment the valine residue at position 35 of any one of SEQ ID NOs:3-9 is substituted with an amino acid residue independently selected from the group consisting of glycine, alanine, serine, threonine, cysteine, leucine, isoleucine, methionine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, asparagine, glutamine, histidine, lysine and arginine.

15 In one embodiment the residue at position 35 of any one of SEQ ID NOs:3-9 is lysine.

In one embodiment the residue at position 35 of any one of SEQ ID NOs:3-9 is not valine, i.e. is any amino acid except for valine.

20 In one embodiment said Annexin A1 N-terminal-peptide is selected from the group consisting of:

AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDVAA (SEQ ID NO:4; Annexin A1 2-50),

AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDV (SEQ ID NO:5; Annexin A1 2-48),

25 AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDVAA (SEQ ID NO:7; Annexin A1 2-50 V24L), and

AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV (SEQ ID NO:8; Annexin A1 2-48 V24L),

30 and a variant of any one of SEQ ID NOs:7-9, wherein said variant comprises 1 to 6 individual amino acid substitutions, such as 1 amino acid substitution, such as 2 amino acid substitutions, such as 3 amino acid substitutions, such as 4 amino acid substitutions, such as 5 amino acid substitutions, such as 6 individual amino acid substitutions;

such as wherein said variant comprises V24L.

35

In one embodiment said Annexin A1 N-terminal-peptide is selected from the group consisting of:

AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDVAA (SED ID NO:4; Annexin A1 2-50) and

5 AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDV (SED ID NO:5; Annexin A1 2-48).

In one embodiment said Annexin A1 N-terminal-peptide is selected from the group consisting of:

10 AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDVAA (SED ID NO:7; Annexin A1 2-50 V24L), and

AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV (SED ID NO:8; Annexin A1 2-48 V24L).

15 In one embodiment said Annexin A1 N-terminal-peptide is

AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV (SED ID NO:8; Annexin A1 2-48 V24L).

20 A fragment and a variant of an Annexin A1 N-terminal-peptide as disclosed herein are in one embodiment equivalent to a functional fragment and/or a functional variant of said Annexin A1 N-terminal-peptide.

A functional variant or functional fragment means that the variant or fragments essentially retains the functionality of the peptide from which it is derived.

25

An Annexin A1 N-terminal-peptide, or a variant or a fragment thereof as defined herewith, including functional variants thereof, according to the present disclosure in one embodiment activates and/or stimulates one or more of Formyl Peptide Receptor 1 (FPR1), Formyl Peptide Receptor 2 (FPR2) and Formyl Peptide Receptor 3 (FPR3).

30

An Annexin A1 N-terminal-peptide, or a variant or a fragment thereof as defined herewith, is in one embodiment a ligand and/or agonist of one or more of Formyl Peptide Receptor 1 (FPR1), Formyl Peptide Receptor 2 (FPR2) and Formyl Peptide Receptor 3 (FPR3).

35

The term “agonist” in the present context refers to a peptide as defined herein, capable of binding to, or in some embodiments, capable of binding to at least some extent and/or activating a receptor, or in some embodiments, activating a receptor to at least some extent. For example, a FPR2 agonist is thus capable of binding to and/or
5 activating the FPR2.

An agonist may be an agonist of several different types of receptors, and thus capable of binding and/or activating several different types of receptors. Said agonist can also be a selective agonist which only binds and activates one type of receptor. The term
10 “antagonist” in the present context refers to a substance capable of inhibiting the effect of a receptor agonist.

Full agonists bind (have affinity for) and activate a receptor, displaying full efficacy at that receptor. “Partial agonists” in the present context are peptides able to bind and
15 activate a given receptor, but having only partial efficacy at the receptor relative to a full agonist. Partial agonists can act as antagonists when competing with a full agonist for receptor occupancy and producing a net decrease in the receptor activation compared to the effects or activation observed with the full agonist alone.

20 “Selective agonists” in the present context are compounds which are selective and therefore predominantly bind and activates one type of receptor. Thus a selective FPR2 agonist is selective for the FPR2.

Polypeptides according to the present disclosure are in one embodiment capable of
25 binding and activating to some extent one or several formyl peptide receptors and can have different binding affinities and/or different receptor activation efficacy for different receptors. Affinity refers to the number and size of intermolecular forces between a peptide ligand and its receptor, and residence time of the ligand at its receptor binding site; and receptor activation efficacy refers to the ability of the peptide ligand to produce
30 a biological response upon binding to the target receptor and the quantitative magnitude of this response. In some embodiments, such differences in affinity and receptor activation efficacy are determined by receptor binding/activation studies which are conventional in the art, for instance by generating EC_{50} and E_{max} values for stimulation of ligand binding in cells expressing one or several types of receptors as
35 mentioned herein, or on tissues expressing the different types of receptors. High affinity means that a lower concentration of a ligand is needed to obtain a binding of 50% of

the receptors compared to ligand peptides which have lower affinity; high receptor activation efficacy means that a lower concentration of the peptide is needed to obtain a 50% receptor activation response (low EC₅₀ value), compared to peptides which have lower affinity and/or receptor activity efficacy (higher EC₅₀ value).

5

In one embodiment, the peptides can have differing affinities and/or receptor activation efficacies for two or more of the receptors selected from FPR1, FPR2 and FPR3.

10 The receptor activation potency of peptide agonists can also be measured in p(A₅₀) values which is a conventional method for determining the receptor activation efficacy of an agonist.

In a particular embodiment, a peptide according to the present disclosure has binding affinity and/or receptor efficacy for the Formyl Peptide Receptor 2 (FPR2).

15

In one particular embodiment, a peptide according to the present disclosure is capable of binding to and activating FPR2. In a further embodiment said peptide is a full agonist of FPR2.

20 In one embodiment an Annexin A1 N-terminal-peptide selected from the group consisting of
AMVSEFLKQ AWFIEENEEQE YVQTVKSSKG GPGSAVSPYP TFNPSSDVAA LHKA
(AnxA1 2-54; SEQ ID NO:3),
and a fragment thereof, and a variant thereof, and a variant of a fragment thereof
25 according to the present disclosure,

- 30
- a. binds to one or more of the formyl peptide receptors, including FPR1, FPR2 and FPR3,
 - b. activates and/or stimulates one or more of the formyl peptide receptors, including FPR1, FPR2 and FPR3,
 - c. binds and/or activates FPR2,
 - d. activates immune cells
 - e. activates leukocytes, such as phagocytic leukocytes,
 - f. activates neutrophils and/or monocytes

- g. activates phagocytic leukocytes' effector functions, such as inducing neutrophil chemotaxis, mobilization of neutrophil complement receptor 3 (CR3), and activation of the neutrophil NADPH-oxidase, and/or
- h. induces chemotaxis in phagocytic leukocytes.

5

In one embodiment the Annexin A1 N-terminal-peptide of the present disclosure is N-terminally acetylated (COCH₃ or Ac-).

10

In one embodiment the Annexin A1 N-terminal-peptide of the present disclosure is C-terminally amidated (-NH₂).

It is an aspect of the present disclosure to provide a liquid pharmaceutical formulation of pH > 6,0; or 2 < pH < 3; said formulation comprising

15

- a. an Annexin A1 (AnxA1) N-terminal-peptide, such as a therapeutically effective amount of an Annexin A1 (AnxA1) N-terminal-peptide, selected from the group consisting of

AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDV
AA (SED ID NO:4; Annexin A1 2-50),

20

AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDV
(SED ID NO:5; Annexin A1 2-48),

AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSS
(SED ID NO:6; Annexin A1 2-46),

25

AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV
AA (SED ID NO:7; Annexin A1 2-50 V24L),

AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV
(SED ID NO:8; Annexin A1 2-48 V24L), and

AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSS
(SED ID NO:9; Annexin A1 2-46 V24L),

30

and a variant of any one of SEQ ID NOs:4-9 comprising 1 to 6 individual amino acid substitutions; and

- b. a solvent selected from the group consisting of

- i. water, such as ultrapure water; and

- ii. an essentially non-ionic or low-ionic, and/or essentially isotonic, solution,

35

optionally comprising an isotonicity modifier, such as a carbohydrate and/or a sugar alcohol.

Also disclosed is a liquid pharmaceutical formulation of $\text{pH} > 6,0$; or $2 < \text{pH} < 3$; said formulation comprising

- 5 a. an Annexin A1 (AnxA1) N-terminal-peptide, such as a therapeutically effective amount of an Annexin A1 (AnxA1) N-terminal-peptide, selected from the group consisting of
- AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDV
AA (SED ID NO:4; Annexin A1 2-50),
- 10 AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDV
(SED ID NO:5; Annexin A1 2-48),
- AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSS
(SED ID NO:6; Annexin A1 2-46),
- AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV
AA (SED ID NO:7; Annexin A1 2-50 V24L),
- 15 AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV
(SED ID NO:8; Annexin A1 2-48 V24L), and
- AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSS
(SED ID NO:9; Annexin A1 2-46 V24L),
- and a variant of any one of SEQ ID NOs:4-9 comprising 1 to 6 individual
- 20 amino acid substitutions; and
- b. a solvent selected from the group consisting of
- i. water, such as ultrapure water; and
- ii. a solution having low ionic strength, such as an ionic strength of
1 μM to 50 mM , and
- 25 iii. a solution which is water, said solution having a tonicity of 100%
(isotonic) +/- 100%, and
- iv. a solution having low ionic strength, such as an ionic strength of
1 μM to 50 mM , said solution having a tonicity of 100% (isotonic)
+/- 100%.

30

In one embodiment said liquid pharmaceutical formulation has a pH of $\text{pH} \geq 7,4$, such as $\text{pH} \geq 7,5$, such as $\text{pH} \geq 7,6$, such as $\text{pH} \geq 7,7$, such as $\text{pH} \geq 7,8$, such as $\text{pH} \geq 7,9$, such as $\text{pH} \geq 8,0$.

35

In one embodiment said liquid pharmaceutical formulation has a pH of $\text{pH} \geq 8$.

In one embodiment said liquid pharmaceutical formulation has a pH of $\text{pH} \geq 8$; or $2 < \text{pH} < 2,6$.

5 In one embodiment said liquid pharmaceutical formulation has a pH of 8 to 8,5.

In one embodiment said liquid pharmaceutical formulation has a pH of approx. 8,3.

10 In one embodiment said liquid pharmaceutical formulation comprises essentially no fibrils and/or comprises essentially no proteinaceous particles of $\geq 1 \mu\text{m}$, such as $\geq 10 \mu\text{m}$, such as $\geq 100 \mu\text{m}$.

15 In one embodiment said Annexin A1 N-terminal-peptide has an aqueous solubility of at least 0,1 mg/ml, such as at least 0,5 mg/ml, such as at least 1,0 mg/ml, such as at least 1,5 mg/ml, such as at least 2,0 mg/ml, such as at least 2,5 mg/ml, such as at least 3,0 mg/ml, such as at least 3,5 mg/ml, such as at least 4,0 mg/ml, such as at least 5,5 mg/ml, such as at least 5,0 mg/ml, such as at least 7,5 mg/ml, such as at least 10,0 mg/ml liquid pharmaceutical formulation.

20 In one embodiment said liquid pharmaceutical formulation has a tonicity of 100% +/- 20%, such as a tonicity of 80% to 120%; such as 80-85%, such as 85-90%, such as 90-95%, such as 95-100%, such as 100-105%, such as 105-110%, such as 110-115%, such as a tonicity of 115-120%.

25 In one embodiment there is provided a liquid pharmaceutical formulation wherein

- a. the solution has a pH of $\text{pH} \geq 7,4$, such as $\text{pH} \geq 7,5$, such as $\text{pH} \geq 7,6$, such as $\text{pH} \geq 7,7$, such as $\text{pH} \geq 7,8$, such as $\text{pH} \geq 7,9$, such as $\text{pH} \geq 8,0$, such as $\text{pH} \geq 8,3$, and/or
- b. the solution has an ionic strength of 1 μM to 50 mM, and/or
- 30 c. the solution has a tonicity of 100% (isotonic) +/- 20%, and/or
- d. the Annexin A1 N-terminal-peptide has an aqueous solubility of at least 0,1 mg/ml, such as at least 0,5 mg/ml, such as at least 1,0 mg/ml, such as at least 1,5 mg/ml, such as at least 2,0 mg/ml, such as at least 2,5 mg/ml, such as at least 3,0 mg/ml, such as at least 3,5 mg/ml, such as

- at least 4,0 mg/ml, such as at least 5,5 mg/ml, such as at least 5,0 mg/ml, such as at least 7,5 mg/ml, such as at least 10,0 mg/ml; and/or
- 5 e. the formulation has a concentration of said Annexin A1 N-terminal-peptide of 0,1 to 10 mg/ml, such as 0,1 to 0,5 mg/ml, such as 0,5 to 1 mg/ml, such as 1 to 2 mg/ml, such as 2 to 3 mg/ml, such as 3 to 4 mg/ml, such as 4 to 5 mg/ml, such as 5 to 6 mg/ml, such as 6 to 7 mg/ml, such as 7 to 8 mg/ml, such as 8 to 9 mg/ml, such as 9 to 10 mg/ml.
- 10 In one embodiment said liquid pharmaceutical formulation comprises one or more isotonicity modifiers.
- In one embodiment said liquid pharmaceutical formulation comprises one or more isotonicity modifiers selected from the group consisting of: sucrose, trehalose,
- 15 mannose, ribose, maltose, glucose, lactose, galactose, arabinose, mannitol, sorbitol, inositol, glycerol, xylitol, propylene glycol, polyethylene glycols (PEGs) and polypropylene/ ethylene glycol copolymer; such as comprises sucrose and/or mannitol.
- In one embodiment said liquid pharmaceutical formulation comprises one or more isotonicity modifiers selected from the group consisting of: sucrose and mannitol.
- 20 In one embodiment said liquid pharmaceutical formulation comprises one or more buffers.
- 25 In one embodiment said liquid pharmaceutical formulation comprises one or more buffers selected from the group consisting of an acetate buffer, TRIS, amine-containing buffers, amino-acid based buffers such as lysine, hydroxy-lysine, histidine and glycylglycine, non-phosphate buffers, bicarbonate buffers, Polysorbate-80 (e.g. Tween 80), HEPES and borate.
- 30 In one embodiment said liquid pharmaceutical formulation comprises approx. 4% mannitol, approx. 1% sucrose, approx. 10 mM glycylglycine, approx. 0,01% polysorbate80, at a pH of approx 8,3.

In one embodiment said variant of any one of SEQ ID NOs:4-9 comprises 3 individual amino acid substitutions.

5 In one embodiment said variant of any one of SEQ ID NOs:4-9 comprises 2 individual amino acid substitutions.

In one embodiment said variant of any one of SEQ ID NOs:4-9 comprises 1 amino acid substitution.

10 In one embodiment said Annexin A1 (AnxA1) N-terminal-peptide is C-terminally amidated.

Method of treatment

15 The pharmaceutical formulations as disclosed herein are particularly effective for use in the treatment of ischemic and inflammatory conditions.

In one embodiment there is provided a liquid pharmaceutical formulation, a lyophilized pharmaceutical formulation, or a reconstituted liquid pharmaceutical formulation (or, solution) as disclosed herein for use as a medicament.

20 In one embodiment there is provided a liquid pharmaceutical formulation, a lyophilized pharmaceutical formulation, or a reconstituted solution as disclosed herein for use in the treatment of an ischemic condition and/or an inflammatory condition.

25 In one embodiment there is provided the use of a liquid pharmaceutical formulation, a lyophilized pharmaceutical formulation, or a reconstituted solution as disclosed herein for the manufacture of a medicament for use in the treatment of an ischemic condition and/or an inflammatory condition.

30 In one embodiment there is provided a method of treatment of an ischemic condition and/or an inflammatory condition, said method comprising one or more steps of administering a liquid pharmaceutical formulation, a lyophilized pharmaceutical formulation, or a reconstituted solution as disclosed herein.

In one embodiment there is provided a liquid pharmaceutical formulation of pH > 6, said formulation comprising

- 5 a. a therapeutically effective amount of an Annexin A1 (AnxA1) N-terminal-peptide selected from the group consisting of
AMVSEFLKQ AWFIEENEEQE YVQTVKSSKG GPGSAVSPYP
TFNPSSDVAA LHKA (AnxA1 2-54; SEQ ID NO:3),
and a fragment thereof, and a variant thereof, and a variant of a fragment thereof; and
- 10 b. a solvent selected from the group consisting of
- i. water, such as ultrapure water; and
- ii. an essentially non-ionic or low-ionic, and/or essentially isotonic, solution, optionally comprising an isotonicity modifier, such as a carbohydrate and/or a sugar alcohol,
and optionally a buffer,
- 15 for use in the treatment of an ischemic condition and/or an inflammatory condition.

In one embodiment there is provided a reconstituted solution comprising an Annexin A1 N-terminal-peptide, wherein said solution is obtained by

- 20 a. providing a lyophilized pharmaceutical formulation according to the present disclosure, and
- b. dissolving said lyophilized pharmaceutical formulation in a solvent,
for use in the treatment of an ischemic condition and/or an inflammatory condition.

25 In some embodiments of the present disclosure, said treatment is prophylactic, ameliorative or curative.

In some embodiments of the present disclosure, said ischemic condition and/or inflammatory condition is acute, subacute or chronic.

30 *Administration routes*

It will be appreciated that the preferred route of administration will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated, the location of the tissue to be treated in the body and the active ingredient chosen.

35

In one embodiment of the present disclosure, the route of administration allows for introducing the pharmaceutical formulation comprising Annexin A1 (AnxA1) N-terminal-peptide into the blood stream to ultimately target the sites of desired action.

5 In one embodiment of the present disclosure the routes of administration is any suitable routes, such as an *enteral route* (including the oral, rectal, nasal, pulmonary, buccal, sublingual, transdermal, intracisternal and intraperitoneal administration), and/or a *parenteral route* (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal administration). Appropriate dosage forms may be
10 prepared by conventional techniques.

Parenteral administration is any administration route not being the oral/enteral route whereby the medicament avoids first-pass degradation in the liver. Accordingly, parenteral administration includes any injections and infusions, for example bolus
15 injection or continuous infusion, such as intravenous administration, intramuscular administration or subcutaneous administration. Furthermore, parenteral administration includes inhalations and topical administration.

Accordingly, the pharmaceutical formulations according to the present disclosure is in
20 one embodiment administered topically to cross any mucosal membrane of an animal to which the formulation is to be given, e.g. in the nose, vagina, eye, mouth, genital tract, lungs, gastrointestinal tract, or rectum, for example the mucosa of the nose, or mouth, and accordingly, parenteral administration may also include buccal, sublingual, nasal, rectal, vaginal and intraperitoneal administration as well as pulmonary and
25 bronchial administration by inhalation or installation. In some embodiments, the formulations as disclosed herein are administered topically to cross the skin.

In one embodiment of the present disclosure, the intravenous, subcutaneous and intramuscular forms of parenteral administration are employed.

30

In one embodiment of the present disclosure, the pharmaceutical formulations as disclosed herein is used as a local treatment, i.e. is introduced directly to the site(s) of action. Accordingly, the pharmaceutical formulations may be applied to the skin or

mucosa directly, or may be injected into the site of action, for example into the diseased tissue or to an end artery leading directly to the diseased tissue.

5 In a preferred embodiment the pharmaceutical formulations as disclosed herein is administered via the parenteral route. Preferred parenteral routes for administration of the pharmaceutical formulations of the present disclosure include intravenous, intramuscular, subcutaneous, intraperitoneal, intraarterial, nasal, pulmonary and buccal routes. Most preferred routes include intravenous, intraperitoneal, intramuscular and subcutaneous routes of administration.

10

Administration and dosage

According to the present disclosure, the pharmaceutical formulations comprising Annexin A1 N-terminal-peptides as provided herein are in one embodiment administered to individuals in need thereof in pharmaceutically effective doses or a therapeutically effective amount.

15

A therapeutically effective amount of an Annexin A1 N-terminal-peptide according to the present disclosure is in one embodiment an amount sufficient to cure, prevent, reduce the risk of, alleviate or partially arrest the clinical manifestations of a given disease or disorder and its complications. The amount that is effective for a particular therapeutic purpose will depend on the severity and the sort of the disorder as well as on the weight and general state of the subject. An amount adequate to accomplish this is defined as a "therapeutically effective amount".

20

25 In one embodiment the pharmaceutical formulation of the present disclosure is administered in doses of from 1 µg/day to 100 mg/day; such as from 1 µg/day to 10 µg/day, such as 10 µg/day to 100 µg/day, such as 100 µg/day to 250 µg/day, such as 250 µg/day to 500 µg/day, such as 500 µg/day to 750 µg/day, such as 750 µg/day to 1 mg/day, such as 1 mg/day to 2 mg/day, such as 2 mg/day to 5 mg/day, or such as 5 mg/day to 10 mg/day, such as 10 mg/day to 20 mg/day, such as 20 mg/day to 30 mg/day, such as 30 mg/day to 40 mg/day, such as 40 mg/day to 50 mg/day, such as 50 mg/day to 75 mg/day, or such as 75 mg/day to 100 mg/day.

30

In one embodiment of the present disclosure, one single dose of the pharmaceutical formulation of the present disclosure is administered and may comprise of from 1 µg/kg

35

body weight to 100 mg/kg body weight; such as from 1 to 10 µg/kg body weight, such as 10 to 100 µg/day, such as 100 to 250 µg/kg body weight, such as 250 to 500 µg/kg body weight, such as 500 to 750 µg/kg body weight, such as 750 µg/kg body weight to 1 mg/kg body weight, such as 1 mg/kg body weight to 2 mg/kg body weight, such as 2 to 5 mg/kg body weight, such as 5 to 10 mg/kg body weight, such as 10 to 20 mg/kg body weight, such as 20 to 30 mg/kg body weight, such as 30 to 40 mg/kg body weight, such as 40 to 50 mg/kg body weight, such as 50 to 75 mg/kg body weight, or such as 75 to 100 mg/kg body weight.

10 In one embodiment, a dose according to the present disclosure is administered one or several times per day, such as from 1 to 6 times per day, such as from 1 to 5 times per day, such as from 1 to 4 times per day, such as from 1 to 3 times per day, such as from 1 to 2 times per day, such as from 2 to 4 times per day, such as from 2 to 3 times per day.

15

Sequences

Full length Annexin A1 (homo sapiens) has the following sequence:

>sp|P04083|ANXA1_HUMAN Annexin A1 OS=Homo sapiens GN=ANXA1 PE=1 SV=2

20 MAMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDVAALHKAIMV
 KGVDEATIIDILTKRNNAQRQQIKAAYLQETGKPLDETLKKALTGHLEEVVLALLKTPAQ
 FDADELRAAMKGLGTDEDTLIEILASRTNKEIRDINRVYREELKRDLAKDITSDTSGDFR
 NALLSLAKGDRSEDFGVNEDLADSDARALYEAGERRRKGTDVNVFNTILTTRSYPQLR
 RVFQKYTKYSKHDMNKVLDLELKGDIKCLTAIVKCATSKPAFFAEKLNHQAAMKGVGTR
 25 HKALIRIMVSRSEIDMNDIKAFYQKMYGISLCQAILDETSGDYEKILVALCGGN (SEQ ID
 NO:1).

MAMVSEFLKQ AWFIEENEEQE YVQTVKSSKG GPGSAVSPYP TFNPSSDVAA LHKA
 (AnxA1 1-54; SEQ ID NO:2)

30 AMVSEFLKQ AWFIEENEEQE YVQTVKSSKG GPGSAVSPYP TFNPSSDVAA LHKA
 (AnxA1 2-54; SEQ ID NO:3)

AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDVAA (SED ID
 NO:4; Annexin A1 2-50)

AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDV (SED ID NO:5; Annexin A1 2-48)

AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSS (SED ID NO:6; Annexin A1 2-46)

5 AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDVA (SED ID NO:7; Annexin A1 2-50 V24L)

AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV (SED ID NO:8; Annexin A1 2-48 V24L)

10 AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSS (SED ID NO:9; Annexin A1 2-46 V24L)

AMVSEFLKQAWFIENEEQEYVQTVK (SED ID NO:10; Annexin A1 2-26),

AMVSEFLKQAWFIENEEQEYVQTLK (SED ID NO:11; Annexin A1 2-26 V24L)

All peptides are in a preferred embodiment C-terminally amidated (-NH₂).

Examples

General materials and methods

In the following examples, "AnxA1" and reference to 'tested peptide' is identified herein
5 as SED ID NO:8 (Annexin A1 2-48 V24L),
AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV, with a C-
terminal amidation.

Thioflavin T, "ThT"

10 Thioflavin T (IUPAC: 4-(3,6-dimethyl-1,3-benzothiazol-3-ium-2-yl)-N,N-dimethylaniline
chloride; CAS Number: 2390-54-7) hereafter known as ThT (the molecule) and ThT
assay (the assay).

ThT is widely used to visualize and quantify the presence of misfolded peptide and
15 protein aggregates called amyloids or fibrils. ThT is a fluorescent molecule that binds to
inter molecular beta-sheets in peptides and proteins (here AnxA1). When excited
around 450 nm ThT exhibits a stronger fluorescence intensity when bound to amyloids
and fibrils. An increase in fluorescence indicates that more ThT molecules are bound to
the peptide this again indicates that more peptide is misfolded as an amyloid or fibril. A
20 weaker fluorescence intensity is indicative of less amyloids or fibrils present with fewer
intermolecular beta-sheets where ThT can bind.

Thioflavin T assay, "ThT assay"

Some peptides have a tendency to form fibrils and amyloids and the propensity is
25 dependent on the formulation conditions in an unpredictable manor. Fibrillation is a
stochastic process and to avoid long analysis times and both false negatives and
positive results, shear stress is introduced to the sample by rigorous rotation in
microtiter plates while continuously monitoring the fluorescence emission at
approximately 486 nm. An increase in the fluorescence is an indication of the formation
30 of amyloids or fibrils and the time it takes for the fluorescence to start increasing is
known as the lag-time. A faster (short) lag-time is an indication of higher propensity for
the peptide to degrade by formation of fibrils or amyloids.

A ThT fluorescence of 50 AU at t=0 is considered noise or background. Lag time is
35 reported as the time it takes for the signal intensity to exceed 50 AU.

All samples for the ThT assay were filtered through cellulose acetate filters (22 μm cut-off, $\text{Ø} = 13 \text{ mm}$, rinsed with MilliQ[®] water prior to filtration). For each sample, 20 μL ThT of a 1 mM solution was added to 1 mL peptide solution. From this sample mixture, 200 μL was transferred into n wells in a 96 well microtiter plate (n = 3-6). 96-well NUNC plates Bottom optics and Sealing tape, Thermo Scientific[™] Nunc[™] Sealing Tapes, was used. Lag-time is reported as an average of n samples.

A fluorescence plate reader (CLARIOstar[®] Plus, BMG Labtech) was used for the experiments with the following setting: Excitation wavelength 450 nm; Dichroic filter 465 nm; Emission wavelength 486 nm; Focal height 3.5 mm; Gain 1000; Number of cycles 960; Cycle time 360 s; Number of flashes per well 20; Temperature 25°C; Shake mode orbital, Frequency of 300 rpm, 200 s, and shake after each cycle.

15 ThT assay – lag-time

If possible, the average of all ThT data replicates are used for ThT lag-time determination. In case of very stochastic data, worst-case data is used for lag-time evaluation. ThT lag-time was determined using either a 1-step or 2-step sigmoidal curve. In cases where the fibrillation did not follow a sigmoidal curve or did not reach plateau within the experimental time, the lag-time was evaluated as the time it takes for the signal to exceed 50 AU.

Determination of concentration using UV-VIS

The concentration of AnxA1 was determined using UV-VIS spectroscopy using a Nanodrop 2000c from Thermo scientific and an extinction coefficient of $A_{280}^{0.1\%} = 1.64 \text{ ml mg}^{-1}\text{cm}^{-1}$.

Dissolution time

The peptide was initially wetted with a small amount of solvent and left for 5 minutes and following added the full amount of solvent. The solution was swirled by hand and observation of final dissolution time noted.

The solutions intended for lyophilization were dissolved by wetting and following added the rest of the solution. Due to the large volume the five formulations were left on a slow rocker for dissolution.

Lyophilization

Samples were prepared prior to lyophilization and stored at 80°C overnight. The samples were prepared with 2 mL AnxA1 solutions in 6R vials, (clear Fiolax, Buch & Holm) with stoppers (20 mm Lyo NovaPure, West Pharma). Samples were placed in the freeze dryer (Telstar LyoQuest, Azbil Telstar Technologies S.L.U.) pre-cooled to -55°C. The condenser temperature was kept at -55°C and the pressure at 0.2 mbar for 48 hours. Formulation 1-5 vial 1-5 were placed on the middle shelf in the tower and formulation 1-5 vial 6-10 were placed on the lower shelf. The tower tube (22Ø, 25 cm tall) is placed outside the condenser at ambient temperature with the lower shelf closest to the condenser.

Example 1

All samples contained 0.9 % NaCl (154 mM) in double deionized (Milli Q®) water with pH ranging from 7.1 to 7.4. The concentration of AnxA1 was between 1.6 mg/mL to 20 mg/mL according to table 1.

The data in figure 1 and table 1 shows the results of the ThT assay for AnxA1 at different concentrations with 0.9% NaCl in Milli Q® water. The data clearly shows that at around neutral pH the peptide degrades by the formation of amyloids or fibrils in a concentration dependent manner. At concentrations ≥ 5 mg/mL AnxA1 has already initiated the degradation (fibrillation) before the analysis is started indicating very high fibrillation propensity.

Table 1: sample composition and lag-time for ThT assay indicating a reverse relationship between concentration and stability from the increase in lag-time when concentration is lower.

AnxA1 (mg/mL)	NaCl (%)	pH	Avg. lag-time (h)
1.6	0.9	7.1	28.3
3.2	0.9	7.4	9.3
5.0	0.9	7.3	2.7
6.4	0.9	7.3	0
7.6	0.9	7.3	0
20 mg/mL*	0.9	8.1**	0

*The sample concentration was not determined due to gel-like texture. 20 mg/mL is estimated from the amount weighed into the sample.

** pH value determined is not considered valid due to the gel-like texture of the sample.

Example 2

20 mg freeze-dried AnxA1 was added per mL of 0.9% NaCl (154 mM) in Milli Q[®] at neutral pH and the peptide was not readily dissolved. The peptide suspension was left
5 over night at room temperature on rotation and the next morning the emulsion has turned into an opaque gel like substance. An aliquot was transferred to an Eppendorf tube, spun down and the concentration in the supernatant determined by UV-VIS to approximately 0.17 mg/mL.

The remainder of the peptide suspension was diluted to an assumed concentration of 5
10 mg/mL and 4*1 mL samples were adjusted to pH 2, 4, 6 and 8, (see Figure 2). All 4 vials continued to be opaque indicating limited solubility.

Example 3

Three samples of AnxA1 was prepared at pH 9 in Milli Q[®] water, 0.9 % NaCl (154 mM)
15 at concentrations 3.3, 1.6 and 0.8 mg/mL, respectively. pH was adjusted by addition of 0.1 M NaOH to each of the samples and the concentration determined after centrifugation using UV-VIS spectroscopy. At pH 6.0 the samples became opaque and precipitated immediately below pH 6.0 (cf. Fig 3).

Example 4

1.6 or 3.2 mg AnxA1 was added to Milli Q[®] water at around neutral pH containing different salts (NaCl, CaCl₂, ZnCl₂ or HCl) according to table 2. Dissolution times was observed and the resulting solutions was analyzed using the ThT assay.

25 It is clearly seen that the dissolution time is much faster at low salt concentrations and, at the same time, the lag-time in the ThT assay is longer indicating less propensity to degradation via amyloid or fibril formation. The best stability is observed with no addition of salt where dissolution is less than 5 minutes and lag-time > 50 hours. Neither NaCl, CaCl₂ nor ZnCl₂ decreased the propensity of AnxA1 to degrade via
30 amyloid or fibril formation (cf. Fig. 4).

Table 2: Seven samples of AnxA1 in Milli Q[®] water at around neutral pH containing different salts (NaCl, CaCl₂, ZnCl₂ or HCl). It is clearly seen that the dissolution time is much faster at low salt concentrations and at the same time the lag-time in the ThT assay is longer. The best

stability is observed with no addition of salt where dissolution is less than 5 minutes and lag-time > 50 hours (fibrillation not observed within the maximum assay time).

Anx01 (mg/mL)	NaCl (%)	CaCl ₂ (mM)	ZnCl ₂ (mM)	HCl (mM)	pH	Dissolution time (Notes)	Avg. lag-time (h)
1.6	-	-	-	-	7.6	5 min	> 50.0*
1.6	-	-	-	-	7.5	5 min	> 50.0*
1.6	-	0.77	-	-	7.2	5 min	12.5
1.6	-	0.77	-	-	7.4	10 min	10.8
3.2	0.9	-	-	-	7.2	45 min	9.7
1.6	0.9	0.77	-	-	7.1	35 min	5.4
1.5	0.9	-	0.77	-	N/A	not fully solubilized after more than 2 hours	1.8

* No increase in fluorescence observed within the timeframe of the analysis (50 hours)

5 **Example 5**

Approximately 16 mg/mL AnxA1 was added to milliQ® water. The resulting pH was 7.5. pH was adjusted to pH 10 in one sample using 0.1 M NaOH and to pH 2 using 0.1 M HCl in another sample, according to table 3. The appearance of the solution was noted. At pH ≥ 7.4 the solution was clear. At pH ≤ 7.1 > 2.6 solutions were unclear. At pH ≤ 2.6 the solution was again clear. Data are summarized in Table 3, see also Figure 5.

Table 3: Visual appearance of samples containing AnxA1 at different pH values. A clear solution was observed ≥ 7.4 and from 2.6 – pH 2.0.

pH	Description
≥ 7.4	Clear 15
7.1	Fluffy particles
6.8-6.3	Milky, turbid
6.1-4.2	Gel-like
3.8-3.1	Starts clearing up
2.6-2.0	Clear solution 20

Example 6

AnxA1 samples are dissolved in Milli Q® water or 5% mannitol in Milli Q® water to approximately 18 mg/mL and pH was adjusted using 1.0 M HCl and NaOH. After dissolution visual appearance was noted and a photograph was taken, see Figure 6 and Table 4, and a sample was cleared by centrifugation and the concentration

25

determined in the supernatant using UV-VIS spectroscopy. A clear solution was observed at pH 8 and 10 both with and without 5% Mannitol in Milli Q[®] water. At pH 2, 4 and 6 an unclear and or viscous solution was observed according to Table 4 and Figure 6.

5

Table 4: Concentration of AnxA1 and visual appearance of solution in Milli Q[®] water with and without mannitol from pH 2 to 10. A clear solution is observed at pH 8 and 10

Sample	Sample name in figure 6	pH	Concentration (mg/ml)	Description
Mannitol 5%	Man 2	2.1	15.5	Not fully soluble, Unclear, viscous texture
Mannitol 5%	Man 4	4.0	0.4	Not fully soluble, Unclear/milky, gel-like
Mannitol 5%	Man 6	6.0	0.8	Not fully soluble, Unclear/milky
Mannitol 5%	Man 8	8.0	16.9	Clear
Mannitol 5%	Man 10	10.1	17.6	Clear
Milli-Q [®]	MQ 2	2.1	15.9	Not fully soluble, Clear with viscous texture
Milli-Q [®]	MQ 4	4.0	0.6	Not fully soluble, Unclear/milky, gel-like
Milli-Q [®]	MQ 6	6.0	1.9	Not fully soluble, Unclear/milky
Milli-Q [®]	MQ 8	8.1	17.0	Clear
Milli-Q [®]	MQ 10	10.1	17.6	Clear

Example 7

10 Isotonic samples containing 1.5 – 1.6 mg/mL AnxA1 and a tonicity provider (isotonicity modifier) was prepared around neutral pH according to the specification in table 5. All samples were observed as clear solutions. The samples were subjected to the ThT assay previously described, where a higher lag-time was observed when using sucrose and mannitol as tonicity providers compared to using trehalose and glucose. The data
15 presented in Table 5 is illustrated graphically in Figure 7.

Table 5: Isotonic samples containing 1.5 – 1.6 mg/mL AnxA1 was prepared around neutral pH according to the specification presented herein.

AnxA1 (mg/mL)	Glucose (wt.%)	Sucrose (wt.%)	Mannitol (wt.%)	Trehalose (wt.%)	pH	Avg- lag time (h)	Visual appearance
1.5	5	-	-	-	7.1	21.7	Clear
1.6	-	10	-	-	7.2	65*	Clear
1.6	-	-	5	-	6.7	65*	Clear
1.6	-	-	-	10	7.2	33.3	Clear

*No increase in fluorescence observed within the timeframe of the analysis (65 hours)

Example 8

5 Samples containing AnxA1 at different concentrations were prepared in Milli Q® water according to table 6. A reference sample was prepared in Saline, 0.9% NaCl (154 mM NaCl). The lag-time was determined using the ThT assay previously described. In Milli Q® water it is clear that higher degradation propensity via amyloid or fibril formation is observed at higher concentration of AnxA1. It is additionally observed that all solutions of AnxA1 in Milli Q water are more stable than the reference sample in saline (154 mM NaCl).

10

Table 6: Lag-time data determined using the ThT assay of AnxA1 samples in Milli Q® water at different concentrations compared to an Anx01 sample in 0.9% (154 mM) NaCl. All samples had a pH of 7.4

AnxA1 (mg/mL)	Solubilized in	pH	Avg. lag-time (h)
1.7	Milli-Q® water	7.4	65*
3.1	Milli-Q® water	7.4	50.4
3.2	Saline (0.9% NaCl)	7.4	5.6
4.6	Milli-Q® water	7.4	61.4
6.1	Milli-Q® water	7.4	29.6
8.0	Milli-Q® water	7.4	11.5

15 *No increase in fluorescence observed within the timeframe of the analysis (65 hours)

Example 9

ThT assay was used to assess the physical stability (fibrillation propensity) of AnxA1. The physical stability was tested in glycyl-glycine buffer pH 8.0 and tris buffer pH 7.4 with either sucrose, mannitol or sorbitol as isotonicity modifier to provide an isotonic solution, the concentration of AnxA1 was between 1.5 mg/mL and 4.8 mg/mL

20

The Lag-time is > 65 hours (the ThT assay is running) in all samples containing 10 mM glycyl-glycine, pH 8 independent of the concentration of AnxA1 and isotonicity modifier.

- 5 In 10 mM tris, pH 7.5, fibrillation is observed after 10.7 to 11.1 hours in all samples at the higher concentrations (4.7 mg/mL). At lower concentration 1.5 mg/mL in 10% sucrose the lag-time is 42.8 hours and at 1.7 mg/mL containing 5% mannitol or sorbitol the lag-time is > 65 hours.

10 Table 7:

AnxA1 (mg/mL)	Isotonicity provider	Mann. (wt.%)	Sorb. (wt.%)	Sucr. (wt.%)	Hist. (mM)	Tris (mM)	Glycyl glycine (mM)	pH	Lag-time (hours)
4.8	Mannitol	5	-	-	10	-	-	6.6	42.1
4.8	Sorbitol	-	5	-	10	-	-	6.7	21.3
4.8	Sucrose	-	-	10	10	-	-	6.6	48.8
1.7	Mannitol	5	-	-	-	10	-	7.5	65*
1.7	Sorbitol	-	5	-	-	10	-	7.6	65*
1.5	Sucrose	-	-	10	-	10	-	7.5	42.8
4.7	Mannitol	5	-	-	-	10	-	7.5	10.7
4.7	Sorbitol	-	5	-	-	10	-	7.5	10.8
4.7	Sucrose	-	-	10	-	10	-	7.5	11.1
1.6	Mannitol	5	-	-	-	-	10	8.0	65*
1.7	Sorbitol	-	5	-	-	-	10	8.0	65*
1.6	Sucrose	-	-	10	-	-	10	8.0	65*
3.1	Mannitol	5	-	-	-	-	10	8.0	65*
3.2	Mannitol	5	-	-	-	-	10	8.0	65*
3.3	Mannitol	5	-	-	-	-	10	8.0	65*
4.7	Mannitol	5	-	-	-	-	10	8.0	65*
4.6	Sorbitol	-	5	-	-	-	10	8.0	65*
4.8	Sucrose	-	-	10	-	-	10	7.9	65*

Mann.: Mannitol, Sorb.: Sorbitol, Sucr.: Sucrose, Hist.: Histidine, Tris: Tris-buffered saline (TBS).

*No increase in fluorescence observed within the timeframe of the analysis (65 hours)

Example 10

The ThT assay was used to assess the physical stability and fibrillation propensity of AnxA1. A design of experiment was performed according to table 8 in 10-50 mM glycyl-glycine buffer, pH 7.4 -8.5, with sucrose, mannitol or mannitol/sucrose at AnxA1 concentrations between 1.5 and 8.4 mg/mL.

The physical stability of AnxA1 increases (longer lag-time) with increasing pH from 7.4 to 8.5. The physical stability decreases (shorter lag-time) with increasing glycyl-glycine buffer concentration from 10 to 50 mM. The effect of the isotonicity modifier used (mannitol, sucrose and mannitol/sucrose) had a negligible effect on the physical stability (lag-time).

Based on the experimental data from the DoE the effect of buffer concentration, AnxA1 concentration and pH on lag-time was modeled and plotted in three dimensional contour plots in figure 10 and figure 11.

Table 8:

AnxA1 concentration (mg/mL)	Mann. (wt. %)	Sucr. (wt. %)	Glycylglycine (mM)	pH	Lag-time (hours)
1.5	5	-	10	7.4	>65*
8.1	5	-	10	7.4	13.7
1.5	5	-	50	7.5	>65
8.0	5	-	50	7.5	3.1
1.5	4	2.5	10	7.5	>65
8.0	4	2.5	10	7.5	15.1
7.9	-	10	10	7.5	23.8
1.5	4	2.5	50	7.6	>65
8.0	4	2.5	50	7.6	3.3
1.6	-	10	50	7.6	64.7
4.7	-	10	30	8.0	>65
4.6	-	10	30	8.0	39
4.7	-	10	30	8.0	50
4.0	5	-	10	8.2	>65
8.4	5	-	10	8.2	41

8.1	-	10	10	8.2	>65
1.6	5	-	e	8.3	>65
8.0	4	2.5	10	8.3	>65
1.5	-	10	10	8.3	>65
1.6	4	2.5	10	8.4	>65
8.0	5	-	50	8.5	41.7
1.4	4	2.5	50	8.5	>65
7.8	4	2.5	50	8.5	31.5
1.4	-	10	50	8.5	>65
7.7	-	10	50	8.5	29.5

Mann.: Mannitol, Sucr.: Sucrose.

*No increase in fluorescence observed within the timeframe of the analysis (65 hours)

Example 11

5 Accelerated stability study.

Five formulations (Form 1-5) of AnxA1 was prepared as presented in table 9. Samples were lyophilized according to the procedure previously described. The chemical stability of the samples was determined as purity of AnxA1 by RP-HPLC (Reversed phase HPLC) in a 6 month stability study at 5°C and 40°C according to table 10.

10

AnxA1 is observed to be physically stable (lag-time > 60 hours) in samples of all compositions at pH 8.3 (formulation 1, 2, 3 & 5). At pH 7.5 the physical stability is less as observed by the shorter lag-time of 34.7 hours. In saline (0.9 wt% NaCl) and Pbs buffer the physical stability is lower as observed from the short lag-times of 8.8 and 5.6 hours, respectively.

15

AnxA1 is observed to be more chemically stable (higher purity) in samples with a combination of mannitol and sucrose as isotonicity modifiers (Form 2, Form 3, Form 4 and Form 5) in comparison to the sample having only mannitol as an isotonicity modifier (Form 1). Sucrose thus increases chemical stability of AnxA1 in the freeze-dried cake.

20

Table 9:

	Tween 80 (%)	Glygly (mM)	Sucr. (wt%)	Mann. (wt%)	NaCl (Wt%)
Form 1	-	10	0	5	-

Form 2	-	10	1	4	-
Form 3	-	-	1	4	-
Form 4	-	10	1	4	-
Form 5	0.01	10	1	4	-
Saline	-	-	-	-	0.9
Pbs*	-	-	-	-	-

Cont.	Peptide (mg/mL)	pH	ThT Lag time (hrs)	Remarks
Form 1	5	8.3	>60	-
Form 2	5	8.3	>60	-
Form 3	5	8.3	>60	-
Form 4	5	7.5	34.7	-
Form 5	5	8.3	>60	-
Saline	3.6	-	8.8	Reference for ThT assay
Pbs*	4.6	7.4	5.6	Reference for ThT assay

Glygly: Glycylglycine, Sucr.: Sucrose, Mann.: Mannitol.

*Dulbecco's phosphate buffered saline from Merck.

5

Table 10:

	Temp	t0	1M	2M	3M	6M
Form 1	5	97,3			96,4	
	40	97,3	92,4	89,0	82,9	79,3
Form 2	5	97,3			96,6	
	40	97,3	97,2	96,8	95,9	94,9
Form 3	5	97,3			96,6	
	40	97,3	97,2	96,8	96,0	95,5
Form 4	5	97,3			96,7	
	40	97,3	97,2	96,8	96,1	95,5
Form 5	5	97,1			96,7	
	40	97,1	96,8	96,3	95,7	93,9

Example 12

10 Stability at hypertonic and hypotonic solutions.

Nine formulations of AnxA1 was prepared as presented in table 11 below, including a positive control for the ThT assay. The samples were analysed using the ThT assay using the procedures previously described with n=3 for samples containing NaHCO₃ and n=4 for samples containing glycyglycine.

5

Fibrillation is observed only in the positive control sample in 0.9% saline. No fibrillation was observed neither in NaHCO₃ nor in glycyglycine buffer at 20% hypotonicity, and at 20% and 100% hypertonicity.

10 **Table 11:**

AnxA1 (mg/mL)	Tonicity (%)	NaCl (wt %)	Mann. (wt.%)	Sucr. (wt.%)	NaHCO ₃ (mM)	Glygly (mM)	pH	Lag-time (hours)
4	100	0.9	-	-	-	-	-	8.2*
5	80	-	3.2	0.8	-	10	8.40	< 60
5	120	-	4.8	1.2	-	10	8.41	< 60
5	200	-	8.0	2.0	-	10	8.40	< 60
5	100	-	4.0	1.0	-	10	8.39	< 60
5	100	-	4.0	1.0	10	-	8.40	< 60
5	80	-	3.2	0.8	10	-	8.41	< 60
5	120	-	4.8	1.2	10	-	8.40	< 60
5	200	-	8.0	2.0	10	-	8.44	< 60

Glygly: Glycyglycine, Sucr.: Sucrose, Mann.: Mannitol. *Positive control sample in 0,9 % saline

15 **ITEMS**

1. A liquid pharmaceutical formulation of pH > 6; or 2 < pH < 3; said formulation comprising

20

a. an Annexin A1 (AnxA1) N-terminal-peptide, such as a therapeutically effective amount of an AnxA1 peptide, selected from the group consisting of

AMVSEFLKQ AWFIEENEEQE YVQTVKSSKG GPGSAVSPYP
TFNPSSDVAA LHKA (AnxA1 2-54; SEQ ID NO:3),

and a fragment thereof, and a variant thereof, and a variant of a fragment thereof; and

25

b. a solvent selected from the group consisting of

i. water, such as ultrapure water; and

- ii. an essentially non-ionic or low-ionic, and/or essentially isotonic, solution,
optionally comprising an isotonicity modifier, such as a carbohydrate and/or a sugar alcohol.

5

2. The liquid pharmaceutical formulation according to item 1, wherein $\text{pH} \geq 6,5$.

3. The liquid pharmaceutical formulation according to any of the preceding items, wherein $\text{pH} \geq 6,5$, such as $\text{pH} \geq 7,0$, such as $\text{pH} \geq 7,5$, such as $\text{pH} \geq 8,0$.

10

4. The liquid pharmaceutical formulation according to any of the preceding items, wherein $\text{pH} > 7$.

5. The liquid pharmaceutical formulation according to any of the preceding items, wherein $\text{pH} > 7,4$.

15

6. The liquid pharmaceutical formulation according to any of the preceding items, wherein $\text{pH} > 7,5$.

20

7. The liquid pharmaceutical formulation according to any of the preceding items, wherein $\text{pH} > 8$.

8. The liquid pharmaceutical formulation according to any of the preceding items, wherein $\text{pH} \leq 12$, such as $\text{pH} \leq 11,5$, such as $\text{pH} \leq 11$, such as $\text{pH} \leq 10,5$, such as $\text{pH} \leq 10$, such as $\text{pH} \leq 9,5$, such as $\text{pH} \leq 9$, such as $\text{pH} \leq 8,5$.

25

9. The liquid pharmaceutical formulation according to any of the preceding items, wherein $6 > \text{pH} \leq 6,5$, such as $6,5 \geq \text{pH} \leq 7$, such as $7 \geq \text{pH} \leq 7,5$, such as $7,5 \geq \text{pH} \leq 8$, such as $8 \geq \text{pH} \leq 8,5$, such as $8,5 \geq \text{pH} \leq 9$, such as $9 \geq \text{pH} \leq 9,5$, such as $9,5 \geq \text{pH} \leq 10$, such as $10 \geq \text{pH} \leq 10,5$, such as $10,5 \geq \text{pH} \leq 11$, such as $11 \geq \text{pH} \leq 11,5$, such as $11,5 \geq \text{pH} \leq 12$.

30

10. The liquid pharmaceutical formulation according to any of the preceding items, wherein $7,0 \geq \text{pH} \leq 7,5$, such as $7,5 \geq \text{pH} \leq 8$, such as $8 \geq \text{pH} \leq 8,5$, such as $8,5 \geq \text{pH} \leq 9$, such as $9 \geq \text{pH} \leq 9,5$, such as $9,5 \geq \text{pH} \leq 10$, such as $10 \geq \text{pH} \leq 10,5$; such as wherein $7,0 \geq \text{pH} \leq 7,5$, such as $7,5 \geq \text{pH} \leq 8$, such as $8 \geq \text{pH} \leq 8,5$, such as $8,5 \geq \text{pH} \leq 9$;

35

such as wherein $\text{pH} \geq 7,4$,

such as wherein $8 \geq \text{pH} \leq 8,5$, such as $8,5 \geq \text{pH} \leq 9$;

such as wherein $8 \geq \text{pH} \leq 8,5$.

- 5 11. The liquid pharmaceutical formulation according to any of the preceding items, wherein pH is 7,5, such as 7,6, such as 7,7, such as 7,8, such as 7,9, such as 8,0, such as 8,1, such as 8,2, such as 8,3, such as 8,3, such as 8,4, such as 8,5, such as 8,6, such as 8,7, such as 8,8, such as 8,9, such as 9,0.
- 10 12. The liquid pharmaceutical formulation according to any of the preceding items, wherein $\text{pH} \geq 7,4$, such as $\text{pH} \geq 7,5$, such as $\text{pH} \geq 7,6$, such as $\text{pH} \geq 7,7$, such as $\text{pH} \geq 7,8$, such as $\text{pH} \geq 7,9$, such as $\text{pH} \geq 8,0$.
- 15 13. The liquid pharmaceutical formulation according to any of the preceding items, wherein pH is approx. 8.3.
14. The liquid pharmaceutical formulation according to any of the preceding items, wherein pH is $2 < \text{pH} < 3$, such as $\text{pH} \leq 3,0$, such as $\text{pH} \leq 2,5$, such as pH of approx. 2,5.
- 20 15. The liquid pharmaceutical formulation according to any of the preceding items, wherein $2 < \text{pH} < 2,6$.
- 25 16. The liquid pharmaceutical formulation according to any of the preceding items, wherein $\text{pH} \geq 8$; or $2 < \text{pH} < 2,6$.
17. The liquid pharmaceutical formulation according to any pf the preceding items, said formulation comprises essentially no fibrils.
- 30 18. The liquid pharmaceutical formulation according to any pf the preceding items, said formulation comprises essentially no visible and/or subvisible particles, such as proteinaceous particles.
- 35 19. The liquid pharmaceutical formulation according to any pf the preceding items, said formulation comprises essentially no visible and/or subvisible particles, such as proteinaceous particles, of $\geq 0,1 \mu\text{m}$, such as of $\geq 1 \mu\text{m}$, such as of $\geq 1 \mu\text{m}$, such as of $\geq 10 \mu\text{m}$, such as of $\geq 1 \mu\text{m}$.

20. The liquid pharmaceutical formulation according to any of the preceding items, said formulation
- a. having improved physical stability,
 - b. having improved solubility and/or reduced insolubility, and/or
 - c. having reduced tendency to form fibrils,
- as compared to a liquid pharmaceutical formulation with a pH of $3 < \text{pH} < 6$, such as $3 < \text{pH} < 6,5$, such as $3 < \text{pH} < 7$, such as $3 < \text{pH} < 7,4$; and/or as compared to a saline liquid pharmaceutical formulation; and/or as compared to a solution having an ionic strength of $> 50 \text{ mM}$; and/or as compared to a solution without an isotonicity modifier.
21. The liquid pharmaceutical formulation according to any of the preceding items, said formulation
- a. having improved chemical stability,
 - b. preserves the peptide during freeze-drying and/or
 - c. reduces peptide degradation during lyophilisation,
- as compared to a liquid pharmaceutical formulation with a pH of $3 < \text{pH} < 6$, such as $3 < \text{pH} < 6,5$, such as $3 < \text{pH} < 7$, such as $3 < \text{pH} < 7,4$; and/or as compared to a saline liquid pharmaceutical formulation; and/or as compared to a solution having an ionic strength of $> 50 \text{ mM}$; and/or as compared to a solution without an isotonicity modifier.
22. The liquid pharmaceutical formulation according to any of the preceding items, wherein the Annexin A1 N-terminal-peptide has an aqueous solubility of at least $0,1 \text{ mg/ml}$, such as at least $0,5 \text{ mg/ml}$, such as at least $1,0 \text{ mg/ml}$, such as at least $1,5 \text{ mg/ml}$, such as at least $2,0 \text{ mg/ml}$, such as at least $2,5 \text{ mg/ml}$, such as at least $3,0 \text{ mg/ml}$, such as at least $3,5 \text{ mg/ml}$, such as at least $4,0 \text{ mg/ml}$, such as at least $5,5 \text{ mg/ml}$, such as at least $5,0 \text{ mg/ml}$, such as at least $7,5 \text{ mg/ml}$, such as at least $10,0 \text{ mg/ml}$.
23. The liquid pharmaceutical formulation according to any of the preceding items, comprising said Annexin A1 N-terminal-peptide in a concentration of $0,1$ to 50 mg/ml .
24. The liquid pharmaceutical formulation according to any of the preceding items, comprising said Annexin A1 N-terminal-peptide in a concentration of $0,1$ to $0,5$

mg/ml, such as 0,5 to 1, such as 1 to 2, such as 2 to 3, such as 3 to 4, such as 4 to 5, such as 5 to 6, such as 6 to 7, such as 7 to 8, such as 8 to 9, such as 9 to 10, such as 10 to 11, such as 11 to 12, such as 12 to 13, such as 13 to 14, such as 14 to 15, such as 15 to 16, such as 16 to 17, such as 17 to 18, such as 18 to 19, such as 19 to 20 mg/ml, such as 20 to 21, such as 21 to 22, such as 22 to 23, such as 23 to 24, such as 24 to 25, such as 25 to 26, such as 26 to 27, such as 27 to 28, such as 28 to 29, such as 29 to 30 mg/ml, such as 30 to 31, such as 31 to 32, such as 32 to 33, such as 33 to 34, such as 34 to 35, such as 35 to 36, such as 36 to 37, such as 37 to 38, such as 38 to 39, such as 39 to 40 mg/ml, such as 40 to 41, such as 41 to 42, such as 42 to 43, such as 43 to 44, such as 44 to 45, such as 45 to 46, such as 46 to 47, such as 47 to 48, such as 48 to 49, such as 49 to 50 mg/ml.

25. The liquid pharmaceutical formulation according to any of the preceding items, comprising said Annexin A1 N-terminal-peptide in a concentration of at least 2,2 mg/ml, such as at least 2,5 mg/ml, such as at least 3,0 mg/ml, such as at least 3,5 mg/ml, such as at least 4,0 mg/ml, such as at least 4,5 mg/ml, such as at least 5,0 mg/ml.

26. The liquid pharmaceutical formulation according to any of the preceding items, wherein the solvent is water.

27. The liquid pharmaceutical formulation according to any of the preceding items, wherein the solvent is ultrapure water.

28. The liquid pharmaceutical formulation according to any of the preceding items, wherein said solvent is an essentially non-ionic or low-ionic solution having a low ionic strength.

29. The liquid pharmaceutical formulation according to any of the preceding items, wherein said solvent has low ionic strength, such as an ionic strength of 1 μ M to 50 mM.

30. The liquid pharmaceutical formulation according to any of the preceding items, wherein said solvent has an ionic strength of 1 μ M to 50 mM, such as 1 μ M to 5 μ M, such as 5 to 10 μ M, such as 10 to 25 μ M, such as 25 to 50 μ M, such as 50 to 75 μ M, such as 75 to 100 μ M, such as 100 to 200 μ M, such as 200 to 300

uM, such as 300 to 400 uM, such as 400 to 500 uM, such as 500 to 750 uM, such as 750 to 1000 uM (1 mM), such as 1 mM to 2 mM, such as 2 to 3 mM, such as 3 to 4 mM, such as 4 to 5 mM, such as 5 to 10 mM, such as 10 to 20 mM, such as 20 to 30 mM, such as 30 to 40 mM, such as 40 to 50 mM.

5

31. The liquid pharmaceutical formulation according to any of the preceding items, wherein said solvent is non-saline.

10

32. The liquid pharmaceutical formulation according to any of the preceding items, wherein the solvent is an essentially isotonic solution.

33. The liquid pharmaceutical formulation according to any of the preceding items, wherein the solvent has a tonicity of approx. 100%.

15

34. The liquid pharmaceutical formulation according to any of the preceding items, wherein the solvent has a tonicity of 100% +/- 100%, such as a tonicity of 0,1 % to 200%.

20

35. The liquid pharmaceutical formulation according to any of the preceding items, wherein the solvent has a tonicity of 100% +/- 100%, such as a tonicity of 0,1 % to 1%, such as 1-5%, such as 5-10%, such as 10-15%, such as 15-20%, such as 20-25%, such as 25-30%, such as 30-35%, such as 35-40%, such as 40-45%, such as 45-50%, such as 50-55%, such as 55-60%, such as 60-65%, such as 65-70%, such as 70-75%, such as 75-80%, such as 80-85%, such as 85-90%, such as 90-95%, such as 95-100%, such as 100-105%, such as 105-110%, such as 110-115%, such as 115-120%, such as 120-125%, such as 125-130%, such as 130-135%, such as 135-140%, such as 140-145%, such as 145-150%, such as 150-155%, such as 155-160%, such as 160-165%, such as 165-170%, such as 170-175%, such as 175-180%, such as 180-185%, such as 185-190%, such as 190-195%, such as 195-200% tonicity.

25

30

36. The liquid pharmaceutical formulation according to any of the preceding items, wherein the solvent has a tonicity of 100% +/- 20%, such as a tonicity of 80% to 120%;.

35

37. The liquid pharmaceutical formulation according to any of the preceding items, wherein the solvent has a tonicity of 80-85%, such as 85-90%, such as 90-95%,

such as 95-100%, such as 100-105%, such as 105-110%, such as 110-115%,
such as 115-120% tonicity.

- 5 38. The liquid pharmaceutical formulation according to any of the preceding items,
wherein the solvent is 0-20% hypertonic, such as 0-5%, such as 5-10%, such
as 10-15%, such as 15-20% hypertonic.
- 10 39. The liquid pharmaceutical formulation according to any of the preceding items,
wherein the solvent is 0-20% hypotonic, such as 0-5%, such as 5-10%, such as
10-15%, such as 15-20% hypotonic.
- 15 40. The liquid pharmaceutical formulation according to any of the preceding items,
wherein said solvent is selected from the group consisting of
- i. water, such as ultrapure water; and
 - ii. a solution having low ionic strength, such as an ionic strength of
1 μ M to 50 mM, and
 - iii. a solution which is water, said solution having a tonicity of 100%
(isotonic) +/- 100%, and
 - iv. a solution having low ionic strength, such as an ionic strength of
20 1 μ M to 50 mM, said solution having a tonicity of 100% (isotonic)
+/- 100%.
- 25 41. The liquid pharmaceutical formulation according to any of the preceding items,
comprising an isotonicity modifier.
- 30 42. The liquid pharmaceutical formulation according to any of the preceding items,
comprising an isotonicity modifier which is a carbohydrate and/or a sugar
alcohol.
- 35 43. The liquid pharmaceutical formulation according to any of the preceding items,
comprising a carbohydrate isotonicity modifier.
44. The liquid pharmaceutical formulation according to any of the preceding items,
comprising a sugar alcohol isotonicity modifier.

45. The liquid pharmaceutical formulation according to any of the preceding items, comprising a carbohydrate isotonicity modifier and a sugar alcohol isotonicity modifier.
- 5 46. The liquid pharmaceutical formulation according to any of the preceding items, wherein said isotonicity modifier is selected from the group consisting of pentose monosaccharides, hexose monosaccharides, disaccharides and trisaccharides.
- 10 47. The liquid pharmaceutical formulation according to any of the preceding items, wherein the carbohydrate isotonicity modifier is selected from the group consisting of: sucrose, trehalose, mannose, ribose, maltose, glucose, lactose, galactose and arabinose.
- 15 48. The liquid pharmaceutical formulation according to any of the preceding items, wherein the sugar alcohol isotonicity modifier is selected from the group consisting of mannitol, sorbitol, inositol, glycerol, xylitol, propylene glycol, polyethylene glycols (PEGs) and polypropylene/ ethylene glycol copolymer.
- 20 49. The liquid pharmaceutical formulation according to any of the preceding items, wherein the solution comprises one or more pentose monosaccharides having a total weight percentage (w/v) of approx. 4.5% (100% isotonic), such as having a total weight percentage (w/v) of 0,1 to 9%, such as 0,1 to 0,5, such as 0,5 to 1,0, such as 1,5 to 2,0, such as 1,5, to 2,0, such as 2,0 to 2,5, such as 2,5 to 3,0, such as 3,0 to 3,5, such as 3,5 to 4,0, such as 4,0 to 4,5, such as 4,5 to 5,0, such as 5,0 to 5,5, such as 5,5 to 6,0, such as 6,0 to 6,5, such as 7,0 to 7,5, such as 7,5 to 8,0, such as 8,0 to 8,5, such as 8,5 to 9,0% (w/v), such as having a total weight percentage (w/v) of 3,6 to 5,4%; such as 3,6 to 3,8, such as 3,8 to 4,0, such as 4,0 to 4,2, such as 4,2 to 4,4, such as 4,4 to 4,6, such as 4,6 to 4,8, such as 4,8 to 5,0, such as 5,0 to 5,2% (w/v).
- 25 30 35 50. The liquid pharmaceutical formulation according to any of the preceding items, wherein the solution comprises one or more hexose monosaccharides having a total weight percentage (w/v) of approx. 5.5% (isotonic), such as having a total weight percentage (w/v) of 0,1 to 10,9%, such as 0,1 to 0,5, such as 0,5 to 1,0, such as 1,5 to 2,0, such as 1,5, to 2,0, such as 2,0 to

2,5, such as 2,5 to 3,0, such as 3,0 to 3,5, such as 3,5 to 4,0, such as 4,0 to 4,5, such as 4,5 to 5,0, such as 5,0 to 5,5, such as 5,5 to 6,0, such as 6,0 to 6,5, such as 7,0 to 7,5, such as 7,5 to 8,0, such as 8,0 to 8,5, such as 8,5 to 9,0, such as 9,0 to 9,5, such as 9,5 to 10,0, such as 10,0 to 10,5, such as 10,5 to 10,9 % (w/v),

5

such as having a total weight percentage (w/v) of 4,4 to 6,6%, such as such as 4,4 to 4,6, such as 4,6 to 4,8, such as 4,8 to 5,0, such as 5,0 to 5,2, such as 5,2 to 5,4, such as 5,4 to 5,6, such as 5,6 to 5,8, such as 5,8 to 6,0, such as 6,0 to 6,2, such as 6,2 to 6,4, such as 6,4 to 6,6% (w/v).

10

51. The liquid pharmaceutical formulation according to any of the preceding items, wherein the solution comprises one or more disaccharides having a total weight percentage (w/v) of approx. 10,3% (isotonic),

15

such as having total weight percentage (w/v) of 0,1 to 20,5%, such as 0,1 to 1, such as 1-2, such as 2-3, such as 3-4, such as 4-5, such as 5-6, such as 6-7, such as 7-8, such as 8-9, such as 9-10, such as 10-11, such as 11-12, such as 12-13, such as 13-14, such as 14-15, such as 15-16, such as 16-17, such as 17-18, such as 18-19, such as 19-20, such as 20-20,5% (w/v), such as having a total weight percentage (w/v) of 8,2 to 12,3%, such as 8,2 to 8,5, such as 8,5 to 9, such as 9 to 9,5, such as 9,5 to 10, such as 10 to 10,5, such as 10,5 to 11, such as 11 to 11,5, such as 11,5 to 12, such as 12 to 12,3% (w/v).

20

52. The liquid pharmaceutical formulation according to any of the preceding items, wherein the solution comprises one or more trisaccharides having a total weight percentage (w/v) of approx. 15,1% (isotonic),

25

such as having a total weight percentage (w/v) of 0,1 to 30,3%, such as such as 0,1 to 1, such as 1-2, such as 2-3, such as 3-4, such as 4-5, such as 5-6, such as 6-7, such as 7-8, such as 8-9, such as 9-10, such as 10-11, such as 11-12, such as 12-13, such as 13-14, such as 14-15, such as 15-16, such as 16-17, such as 17-18, such as 18-19, such as 19-20, such as 20-21, such as 21-22, such as 22-23, such as 23-24, such as 24-25, such as 25-26, such as 26-27, such as 27-28, such as 28-29, such as 29-30, such as 30-30,3% (w/v),

30

such as having a total weight percentage (w/v) of 12,1 to 18,2%, such as 12,1 to 12,5, such as 12,5 to 13, such as 13 to 13,5, such as 13,5 to 14, such as 14

to 14,5, such as 14,5-15, such as 15 to 15,5, such as 15,5 to 16, such as 16 to 16,5, such as 16,5 to 17, such as 17,5 to 18, such as 18 to 18,2% (w/v).

53. The liquid pharmaceutical formulation according to any of the preceding items,
5 wherein the solution comprises trehalose and/or sucrose.
54. The liquid pharmaceutical formulation according to any of the preceding items,
wherein the solution comprises sucrose.
- 10 55. The liquid pharmaceutical formulation according to any of the preceding items,
wherein the solution comprises approx. 10% (w/v) sucrose; such as comprises
8-12% (w/v) sucrose, such as 8-9, such as 9-10, such as 10-11, such as 11-
12% (w/v) sucrose,
such as comprises approx. 1% (w/v) sucrose,
15 such as comprises 1-5% (w/v) sucrose, such as 1-2, such as 2-3, such as 3-4,
such as 4-5 (w/v) sucrose,
such as comprises 0-20% (w/v) sucrose, such as 0,1-1, 1-2, 2-3, 3-4, 4-5, 5-6,
6-7, 7-8, 8-9, 8-9, 9-10, 10-11, 11-12, 12-13, 13-14, 14-15, 15-16, 16-17, 17-18,
18-19, 19-20% (w/v) sucrose.
- 20 56. The liquid pharmaceutical formulation according to any of the preceding items,
wherein the solution comprises mannitol.
- 25 57. The liquid pharmaceutical formulation according to any of the preceding items,
wherein the solution comprises approx. 5% (w/v) mannitol, such as comprises 4
to 6% (w/v) mannitol, such as 4 to 4,5, such as 4,5 to 5, such as 5 to 5,5, such
as 5,5 to 6% mannitol,
such as comprises approx. 4% (w/v) mannitol, such as comprises 3-5% (w/v)
mannitol, such as 3 to 5% (w/v) mannitol, such as 3 to 3,5, such as 3,5 to 4,
30 such as 4 to 4,5, such as 4,5 to 4% mannitol,
such as comprises 0-10% (w/v) mannitol, such as 0,1-1, such as 1-2, such as
2-3, such as 3-4, such as 4-5, such as 5-6, such as 6-7, such as 7-8, such as 8-
9, such as 9-10% (w/v) mannitol.
- 35 58. The liquid pharmaceutical formulation according to any of the preceding items,
wherein the solution comprises mannitol and sucrose.

59. The liquid pharmaceutical formulation according to any of the preceding items, wherein the solution comprises approx. 4% (w/v) mannitol and approx. 2,5% sucrose,
- 5 such as comprises 3 to 5% (w/v) mannitol and 2 to 3% (w/v) sucrose, such as comprises 0 to 8 % (w/v) mannitol and 0 to 5% (w/v) sucrose.
60. The liquid pharmaceutical formulation according to any of the preceding items, wherein
- 10 a. the solution has a pH of $\text{pH} \geq 7,4$, and/or
- b. the solution has a pH of $\text{pH} \geq 7,5$, such as $\text{pH} \geq 7,6$, such as $\text{pH} \geq 7,7$, such as $\text{pH} \geq 7,8$, such as $\text{pH} \geq 7,9$, such as $\text{pH} \geq 8,0$, such as $\text{pH} \geq 8,1$, such as $\text{pH} \geq 8,2$, such as $\text{pH} \geq 8,3$, such as $\text{pH} \geq 8,5$, such as $\text{pH} \geq 8,6$, such as $\text{pH} \geq 8,7$, such as $\text{pH} \geq 8,8$, such as $\text{pH} \geq 8,9$, such as $\text{pH} \geq 9,0$
- 15 and/or
- c. the solution has an ionic strength of 1 μM to 50 mM, and/or
- d. the solution has a tonicity of 100% (isotonic) +/- 20%, and/or
- e. the solution comprises an isotonicity modifier selected from the group consisting of: sucrose, trehalose, mannose, ribose, maltose, glucose,
- 20 lactose, galactose, arabinose, mannitol, sorbitol, inositol, glycerol, xylitol, propylene glycol, polyethylene glycols (PEGs) and polypropylene/ethylene glycol copolymer, and/or
- f. the solution comprises sucrose and/or mannitol, and/or
- g. the Annexin A1 N-terminal-peptide has an aqueous solubility of at least
- 25 0,1 mg/ml, such as at least 0,5 mg/ml, such as at least 1,0 mg/ml, such as at least 1,5 mg/ml, such as at least 2,0 mg/ml, such as at least 2,5 mg/ml, such as at least 3,0 mg/ml, such as at least 3,5 mg/ml, such as at least 4,0 mg/ml, such as at least 5,5 mg/ml, such as at least 5,0 mg/ml, such as at least 7,5 mg/ml, such as at least 10,0 mg/ml, and/or
- 30 h. the solution comprises the Annexin A1 N-terminal-peptide in a concentration of 0,1 to 50 mg/ml.
61. The liquid pharmaceutical formulation according to any of the preceding items further comprising a buffer, such as one or more buffers.
- 35

62. The liquid pharmaceutical formulation according to any of the preceding items, wherein said buffer is selected from the group consisting of Acetate buffer, TRIS, Amine-containing buffers, Amino-acid based buffers such as lysine, hydroxy-lysine histidine and glycyl-glycine, non-phosphate buffers, bicarbonate buffers, Polysorbate-80 (Tween 80), HEPES and borate.
63. The liquid pharmaceutical formulation according to any of the preceding items, further comprising glycyl-glycine and/or polysorbate80.
64. The liquid pharmaceutical formulation according to any of the preceding items, further comprising a preservative.
65. The liquid pharmaceutical formulation according to any of the preceding items, further comprising a preservative selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl, propyl parabens, butyl parabens, methyl parabens and phenol.
66. The liquid pharmaceutical formulation according to any of the preceding items, wherein said Annexin A1 N-terminal-peptide is selected from the group consisting of
AMVSEFLKQ AWFIEENEEQE YVQTVKSSKG GPGSAVSPYP TFNPSSDVAA
LHKA (AnxA1 2-54; SEQ ID NO:3),
and a fragment of SEQ ID NO:3, wherein said fragment comprises 5 to 52 consecutive amino acids of SEQ ID NO:3, such as 5-10, such as 10-15, such as 15-20, such as 20-25, such as 25-30, such as 30-35, such as 35-40, such as 40-45, such as 45-50, such as 50-52 consecutive amino acids of SEQ ID NO:3, and a variant of SEQ ID NO:3, wherein said variant comprises 1 to 6 individual amino acid substitutions, such as 1 amino acid substitution, such as 2 amino acid substitutions, such as 3 amino acid substitutions, such as 4 amino acid substitutions, such as 5 amino acid substitutions, such as 6 individual amino acid substitutions.
67. The liquid pharmaceutical formulation according to any of the preceding items, wherein said fragment of SEQ ID NO:3 comprises or consists of 5 or more consecutive amino acids of SEQ ID NO:3, such as comprises or consists of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,

29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52 consecutive amino acids of SEQ ID NO:3.

- 5 68. The liquid pharmaceutical formulation according to any of the preceding items, wherein said Annexin A1 N-terminal-peptide is selected from the group consisting of:
AMVSEFLKQAWFIENEEQEYVQTVK (SED ID NO:10; Annexin A1 2-26),
and a variant of SEQ ID NO:10, wherein said variant comprises 1 to 6 individual amino acid substitutions, such as 1 amino acid substitution, such as 2 amino acid substitutions, such as 3 amino acid substitutions, such as 4 amino acid substitutions, such as 5 amino acid substitutions, such as 6 individual amino acid substitutions.
- 10
- 15 69. The liquid pharmaceutical formulation according to any of the preceding items, wherein said Annexin A1 N-terminal-peptide is selected from the group consisting of:
AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDVAA (SED ID NO:4; Annexin A1 2-50),
AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDV (SED ID NO:5; Annexin A1 2-48), and
20 AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSS (SED ID NO:6; Annexin A1 2-46),
and a variant of any one of SEQ ID NOs:4-6, wherein said variant comprises 1 to 6 individual amino acid substitutions, such as 1 amino acid substitution, such as 2 amino acid substitutions, such as 3 amino acid substitutions, such as 4 amino acid substitutions, such as 5 amino acid substitutions, such as 6 individual amino acid substitutions.
- 25
- 30 70. The liquid pharmaceutical formulation according to any of the preceding items, wherein the valine (V) at position 24 of any one of SEQ ID NOs:3-6 and 10 is substituted with any other standard or non-standard amino acid.
- 35 71. The liquid pharmaceutical formulation according to any of the preceding items, wherein the valine (V) at position 24 of any one of SEQ ID NOs:3-6 and 10 is substituted with leucine (L).

72. The liquid pharmaceutical formulation according to any of the preceding items, wherein said Annexin A1 N-terminal-peptide is selected from the group consisting of:
- 5 AMVSEFLKQAWFIENEEQEYVQTLK (SED ID NO:11; Annexin A1 2-26 V24L), and a variant of SEQ ID NO:11, wherein said variant comprises 1 to 6 individual amino acid substitutions, such as 1 amino acid substitution, such as 2 amino acid substitutions, such as 3 amino acid substitutions, such as 4 amino acid substitutions, such as 5 amino acid substitutions, such as 6 individual amino acid substitutions.
- 10
73. The liquid pharmaceutical formulation according to any of the preceding items, wherein said Annexin A1 N-terminal-peptide is selected from the group consisting of:
- 15 AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDVAA (SED ID NO:7; Annexin A1 2-50 V24L), AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV (SED ID NO:8; Annexin A1 2-48 V24L), and AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSS (SED ID
- 20 NO:9; Annexin A1 2-46 V24L), and a variant of any one of SEQ ID NOs:7-9, wherein said variant comprises 1 to 6 amino acid substitutions, such as 1 amino acid substitution, such as 2 amino acid substitutions, such as 3 amino acid substitutions, such as 4 amino acid substitutions, such as 5 amino acid substitutions, such as 6 amino acid
- 25 substitutions.
74. The liquid pharmaceutical formulation according to any of the preceding items, wherein the alanine residue at position 10 of any one of SEQ ID NOs:3-11 is substituted with any other standard or non-standard amino acid; such as an
- 30 amino acid residue independently selected from the group consisting of leucine, aspartic acid, methionine, glutamic acid, isoleucine and arginine.
75. The liquid pharmaceutical formulation according to any of the preceding items, wherein the valine residue at position 21 of any one of SEQ ID NOs:3-11 is
- 35 substituted with any other standard or non-standard amino acid; such as an

amino acid residue independently selected from the group consisting of leucine, aspartic acid, methionine, glutamic acid, isoleucine and lysine.

- 5 76. The liquid pharmaceutical formulation according to any of the preceding items, wherein the valine residue at position 35 of any one of SEQ ID NOs:3-9 is substituted with any other standard or non-standard amino acid; such as an amino acid residue independently selected from the group consisting of glycine, alanine, serine, threonine, cysteine, leucine, isoleucine, methionine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, asparagine, 10 glutamine, histidine, lysine and arginine; preferably lysine.
- 15 77. The liquid pharmaceutical formulation according to any of the preceding items, wherein said amino acid substitutions are conservative amino acid substitutions.
- 20 78. The liquid pharmaceutical formulation according to any of the preceding items, wherein said variant of any one of SEQ ID NOs:4-9 comprises 1, 2 or 3 amino acid substitutions, such as 1 or 2 amino acid substitutions, such as 1 amino acid substitution.
- 25 79. The liquid pharmaceutical formulation according to any of the preceding items, wherein said Annexin A1 N-terminal-peptide is selected from the group consisting of:
AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDVAA
(SED ID NO:4; Annexin A1 2-50) and
AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDV (SED
ID NO:5; Annexin A1 2-48).
- 30 80. The liquid pharmaceutical formulation according to any of the preceding items, wherein said Annexin A1 N-terminal-peptide is selected from the group consisting of:
AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDVAA
(SED ID NO:7; Annexin A1 2-50 V24L), and
AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV (SED
35 ID NO:8; Annexin A1 2-48 V24L).

- 5
81. The liquid pharmaceutical formulation according to any of the preceding items, wherein said Annexin A1 N-terminal-peptide is AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV (SED ID NO:8; Annexin A1 2-48 V24L), with a C-terminal amidation.
- 10
82. The liquid pharmaceutical formulation according to any of the preceding items, wherein said said fragment and said variant of an Annexin A1 N-terminal-peptide, are functional fragments and/or functional variants of an Annexin A1 N-terminal-peptide.
- 15
83. The liquid pharmaceutical formulation according to any of the preceding items, wherein said Annexin A1 N-terminal-peptide, or variant or fragment thereof,
- a. binds to one or more of the formyl peptide receptors, including FPR1, FPR2 and FPR3,
 - b. activates and/or stimulates one or more of the formyl peptide receptors, including FPR1, FPR2 and FPR3,
 - c. binds and/or activates FPR2,
 - d. activates immune cells
 - e. activates leukocytes, such as phagocytic leukocytes,
 - 20 f. activates neutrophils and/or monocytes
 - g. activates phagocytic leukocytes' effector functions, such as inducing neutrophil chemotaxis, mobilization of neutrophil complement receptor 3 (CR3), and activation of the neutrophil NADPH-oxidase, and/or
 - h. induces chemotaxis in phagocytic leukocytes.
- 25
84. The liquid pharmaceutical formulation according to any of the preceding items, wherein said Annexin A1 N-terminal-peptide is N-terminally acetylated (COCH₃ or Ac-).
- 30
85. The liquid pharmaceutical formulation according to any of the preceding items, wherein said Annexin A1 N-terminal-peptide is C-terminally amidated (-NH₂).
- 35
86. A process of preparing a liquid pharmaceutical formulation according to any of the preceding items, comprising the steps of
- a. mixing an Annexin A1 N-terminal-peptide with a solvent according to any of the preceding items,

- b. optionally filtering the mixture of step a., and
- c. adjusting the pH of said liquid pharmaceutical formulation to $\text{pH} < 6$; or $2 < \text{pH} < 3$.

- 5 87. The process according to item 84, wherein said pH is adjusted to $6 > \text{pH} \leq 6,5$, such as $6,5 \geq \text{pH} \leq 7$, such as $7 \geq \text{pH} \leq 7,5$, such as $7,5 \geq \text{pH} \leq 8$, such as $8 \geq \text{pH} \leq 8,5$, such as $8,5 \geq \text{pH} \leq 9$, such as $9 \geq \text{pH} \leq 9,5$, such as $9,5 \geq \text{pH} \leq 10$, such as $10 \geq \text{pH} \leq 10,5$, such as $10,5 \geq \text{pH} \leq 11$, such as $11 \geq \text{pH} \leq 11,5$, such as $11,5 \geq \text{pH} \leq 12$.
- 10 88. The process according to item 84, wherein said pH is adjusted to $2 < \text{pH} < 3$, such as $\text{pH} \leq 3,0$, such as $\text{pH} \leq 2,5$, such as approx. pH of 2,5.
- 15 89. A process of preparing a lyophilized pharmaceutical formulation, said process comprising the steps of
- a. providing the liquid pharmaceutical formulation according to any of the preceding items,
 - b. lyophilizing said liquid of step a.
- 20 90. The process according to item 87, wherein said lyophilisation comprises one or more steps of
- a. freezing the liquid pharmaceutical formulation as defined herein above,
 - b. primary drying (sublimation phase), comprising lowering pressure and heating, and
 - 25 c. secondary drying (desorption phase).
91. A lyophilized pharmaceutical formulation obtained by the process according to any one of items 87-88.
- 30 92. The lyophilized pharmaceutical formulation according to any of the preceding claims, which is stable, such as shelf-stable.
93. A method of making a reconstituted solution comprising an Annexin A1 N-terminal-peptide, said method comprising
- 35 a. providing a lyophilized pharmaceutical formulation according to any one of items 87-90, and

b. dissolving said lyophilized pharmaceutical formulation in a solvent.

94. The method according to item 91, wherein said solvent has a $\text{pH} > 6$ and/or said solution has a $\text{pH} > 6$; or $2 < \text{pH} < 3$.

5

95. The method according to item 92, wherein said solvent and/or said solution has $6 > \text{pH} \leq 6,5$, such as $6,5 \geq \text{pH} \leq 7$, such as $7 \geq \text{pH} \leq 7,5$, such as $7,5 \geq \text{pH} \leq 8$, such as $8 \geq \text{pH} \leq 8,5$, such as $8,5 \geq \text{pH} \leq 9$, such as $9 \geq \text{pH} \leq 9,5$, such as $9,5 \geq \text{pH} \leq 10$, such as $10 \geq \text{pH} \leq 10,5$, such as $10,5 \geq \text{pH} \leq 11$, such as $11 \geq \text{pH} \leq 11,5$, such as $11,5 \geq \text{pH} \leq 12$; or $2 < \text{pH} < 3$, such as $\text{pH} \leq 3,0$, such as $\text{pH} \leq 2,5$, such as pH of approx. 2,5.

10

96. The method according to any one of items 91-93, wherein said solvent is selected from the group consisting of

15

- a. water, such as ultrapure water; and
- b. an essentially non-ionic or low-ionic, and/or essentially isotonic, solution, optionally comprising an isotonicity modifier, such as a carbohydrate and/or a sugar alcohol.

20

97. The method according to any one of items 91-94, wherein said solvent is water, such as ultrapure water.

98. The liquid pharmaceutical formulation or the lyophilized pharmaceutical formulation according to any of the preceding items for use as a medicament.

25

99. The liquid pharmaceutical formulation or the lyophilized pharmaceutical formulation according to any of the preceding items for use in the treatment of an ischemic condition and/or an inflammatory condition.

30

CLAIMS

1. A liquid pharmaceutical formulation of $\text{pH} > 6,0$; or $2 < \text{pH} < 3$; said formulation
 5 comprising
- a. an Annexin A1 (AnxA1) N-terminal-peptide, such as a therapeutically effective amount of a peptide, selected from the group consisting of
- AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDV
 AA (SED ID NO:4; Annexin A1 2-50),
 10 AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDV
 (SED ID NO:5; Annexin A1 2-48),
 AMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSS
 (SED ID NO:6; Annexin A1 2-46),
 AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV
 15 AA (SED ID NO:7; Annexin A1 2-50 V24L),
 AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV
 (SED ID NO:8; Annexin A1 2-48 V24L), and
 AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSS
 (SED ID NO:9; Annexin A1 2-46 V24L),
 20 and a variant of any one of SEQ ID NOs:4-9 comprising 1 to 6 individual
 amino acid substitutions; and
- b. a solvent selected from the group consisting of
- i. water, such as ultrapure water; and
- ii. a solution having low ionic strength, such as an ionic strength of
 25 1 μM to 50 mM , and
- iii. a solution which is water, said solution having a tonicity of 100%
 (isotonic) +/- 100%, and
- iv. a solution having low ionic strength, such as an ionic strength of
 30 1 μM to 50 mM , said solution having a tonicity of 100% (isotonic)
 +/- 100%.
2. The liquid pharmaceutical formulation according to claim 1, wherein $\text{pH} \geq 7,4$; or
 $2 < \text{pH} < 2,6$.

3. The liquid pharmaceutical formulation according to any of the preceding claims, wherein $\text{pH} \geq 7,4$, such as $\text{pH} \geq 7,5$, such as $\text{pH} \geq 7,6$, such as $\text{pH} \geq 7,7$, such as $\text{pH} \geq 7,8$, such as $\text{pH} \geq 7,9$, such as $\text{pH} \geq 8,0$.
- 5 4. The liquid pharmaceutical formulation according to any of the preceding claims, wherein $\text{pH} \geq 8$; or $2 < \text{pH} < 2,6$.
- 5 5. The liquid pharmaceutical formulation according to any of the preceding claims, wherein pH is 8 to 8,5.
- 10 6. The liquid pharmaceutical formulation according to any of the preceding claims, wherein pH is $\geq 8,3$.
- 15 7. The liquid pharmaceutical formulation according to any of the preceding claims, said formulation comprising essentially no fibrils and/or comprising essentially no proteinaceous particles of $\geq 1 \mu\text{m}$, such as $\geq 10 \mu\text{m}$, such as $\geq 100 \mu\text{m}$.
- 20 8. The liquid pharmaceutical formulation according to any of the preceding claims, said formulation
 - a. having improved physical stability,
 - b. having improved chemical stability,
 - c. having improved solubility and/or reduced insolubility, and/or
 - d. having reduced tendency to form fibrils, ,as compared to a liquid pharmaceutical formulation with a pH of $3 < \text{pH} < 6$,
25 such as $3 < \text{pH} < 6,5$, such as $3 < \text{pH} < 7$, such as $3 < \text{pH} < 7,4$; and/or as compared to a saline liquid pharmaceutical formulation; and/or as compared to a solution having an ionic strength of $> 50 \text{ mM}$; and/or as compared to a solution without an isotonicity modifier.
- 30 9. The liquid pharmaceutical formulation according to any of the preceding claims, wherein the Annexin A1 N-terminal-peptide has an aqueous solubility of at least $0,1 \text{ mg/ml}$, such as at least $0,5 \text{ mg/ml}$, such as at least $1,0 \text{ mg/ml}$, such as at least $1,5 \text{ mg/ml}$, such as at least $2,0 \text{ mg/ml}$, such as at least $2,5 \text{ mg/ml}$, such as at least $3,0 \text{ mg/ml}$, such as at least $3,5 \text{ mg/ml}$, such as at least $4,0 \text{ mg/ml}$, such
35 as at least $5,5 \text{ mg/ml}$, such as at least $5,0 \text{ mg/ml}$, such as at least $7,5 \text{ mg/ml}$, such as at least $10,0 \text{ mg/ml}$.

10. The liquid pharmaceutical formulation according to any of the preceding claims, wherein the Annexin A1 N-terminal-peptide has an aqueous solubility of at least 0,8 mg/ml, such as at least 1 mg/ml, such as at least 1,6, such as at least 2, such as at least 2,5, such as at least 3, such as at least 3,3, such as at least 3,5 mg/ml.
11. The liquid pharmaceutical formulation according to any of the preceding claims, said formulation having a concentration of said Annexin A1 N-terminal-peptide of 0,1 to 10 mg/ml, such as 0,1 to 0,5 mg/ml, such as 0,5 to 1 mg/ml, such as 1 to 2 mg/ml, such as 2 to 3 mg/ml, such as 3 to 4 mg/ml, such as 4 to 5 mg/ml, such as 5 to 6 mg/ml, such as 6 to 7 mg/ml, such as 7 to 8 mg/ml, such as 8 to 9 mg/ml, such as 9 to 10 mg/ml.
12. The liquid pharmaceutical formulation according to any of the preceding claims, said formulation having a concentration of said Annexin A1 N-terminal-peptide of at least 0,8 mg/ml, such as at least 1 mg/ml, such as at least 1,6, such as at least 2, such as at least 2,5, such as at least 3, such as at least 3,3, such as at least 3,5 mg/ml.
13. The liquid pharmaceutical formulation according to any of the preceding claims, wherein pH >6 and the Annexin A1 N-terminal-peptide has an aqueous solubility of at least 0,8 mg/ml, such as at least 1 mg/ml, such as at least 1,6, such as at least 2, such as at least 2,5, such as at least 3, such as at least 3,3, such as at least 3,5 mg/ml; and/or said formulation having a concentration of said Annexin A1 N-terminal-peptide of at least 0,8 mg/ml, such as at least 1 mg/ml, such as at least 1,6, such as at least 2, such as at least 2,5, such as at least 3, such as at least 3,3, such as at least 3,5 mg/ml.
14. The liquid pharmaceutical formulation according to any of the preceding claims, wherein said solution has an ionic strength of 1 uM to 50 mM.
15. The liquid pharmaceutical formulation according to any of the preceding claims, wherein the solution has a tonicity of 100% (isotonic) +/- 20%, such as a tonicity of 80% to 120%; such as 80-85%, such as 85-90%, such as 90-95%, such as 95-100%, such as 100-105%, such as 105-110%, such as 110-115%, such as a tonicity of 115-120%.

16. The liquid pharmaceutical formulation according to any of the preceding claims,
wherein
- a. the solution has an ionic strength of 1 uM to 50 mM, and
 - b. the solution has a tonicity of 100% (isotonic) +/- 20%.
17. The liquid pharmaceutical formulation according to any of the preceding claims,
wherein
- a. the solution has a pH of pH \geq 7,4, such as pH \geq 7,5, such as pH \geq 7,6,
such as pH \geq 7,7, such as pH \geq 7,8, such as pH \geq 7,9, such as pH \geq 8,0,
and
 - b. the solution has an ionic strength of 1 uM to 50 mM.
18. The liquid pharmaceutical formulation according to any of the preceding claims,
wherein
- a. the solution has a pH of pH \geq 8,0, and
 - b. the solution has an ionic strength of 1 uM to 50 mM.
19. The liquid pharmaceutical formulation according to any of the preceding claims,
wherein
- a. the solution has a pH of pH \geq 7,4, such as pH \geq 7,5, such as pH \geq 7,6,
such as pH \geq 7,7, such as pH \geq 7,8, such as pH \geq 7,9, such as pH \geq 8,0,
and
 - b. the solution has an ionic strength of 1 uM to 50 mM, and
 - c. the solution has a tonicity of 100% (isotonic) +/- 20%.
20. The liquid pharmaceutical formulation according to any of the preceding claims,
wherein
- a. the solution has a pH of pH \geq 8,0, and
 - b. the solution has an ionic strength of 1 uM to 50 mM, and
 - c. the solution has a tonicity of 100% (isotonic) +/- 20%.
21. The liquid pharmaceutical formulation according to any of the preceding claims,
wherein
- a. the solution has a pH of pH \geq 8,3, and
 - b. the solution has an ionic strength of 1 uM to 50 mM, and

c. the solution has a tonicity of 100% (isotonic) +/- 20%.

22. The liquid pharmaceutical formulation according to any of the preceding claims, wherein pH \geq 7,4, such as pH \geq 8,0, such as pH \geq 8,3, and the Annexin A1 N-terminal-peptide has an aqueous solubility of at least 4,0 mg/ml, such as at least 4,5 mg/ml, such as at least 5,0 mg/ml, such as at least 6,0 mg/ml, such as at least 7,0 mg/ml, such as at least 8,0 mg/ml, such as at least 9,0 mg/ml, such as at least 10,0 mg/ml, such as at least 15,0 mg/ml; and/or said formulation having a concentration of said Annexin A1 N-terminal-peptide of at least 4,0 mg/ml, such as at least 4,5 mg/ml, such as at least 5,0 mg/ml, such as at least 6,0 mg/ml, such as at least 7,0 mg/ml, such as at least 8,0 mg/ml, such as at least 9,0 mg/ml, such as at least 10,0 mg/ml, such as at least 15,0 mg/ml.
23. The liquid pharmaceutical formulation according to any of the preceding claims, wherein said solvent comprises one or more isotonicity modifiers, such as a carbohydrate and/or a sugar alcohol.
24. The liquid pharmaceutical formulation according to any of the preceding claims, wherein said isotonicity modifier is selected from the group consisting of pentose monosaccharides, hexose monosaccharides, disaccharides and trisaccharides.
25. The liquid pharmaceutical formulation according to any of the preceding claims, wherein said isotonicity modifier is selected from the group consisting of: sucrose, trehalose, mannose, ribose, maltose, glucose, lactose, galactose, arabinose, mannitol, sorbitol, inositol, glycerol, xylitol, propylene glycol, polyethylene glycols (PEGs) and polypropylene/ ethylene glycol copolymer.
26. The liquid pharmaceutical formulation according to any of the preceding claims, wherein the solution comprises sucrose and/or mannitol.
27. The liquid pharmaceutical formulation according to any of the preceding claims, wherein the solution comprises sucrose.
28. The liquid pharmaceutical formulation according to any of the preceding claims, wherein the solution comprises approx. 4% (w/v) mannitol and/or approx. 1%

sucrose, such as comprises 3 to 5% (w/v) mannitol and/or 0,5 to 2% (w/v) sucrose, such as comprises 0 to 8 % (w/v) mannitol and/or 0 to 5% (w/v) sucrose.

- 5 29. The liquid pharmaceutical formulation according to any of the preceding claims, wherein
- a. the solution has an ionic strength of 1 uM to 50 mM, and
 - b. the solution has a tonicity of 100% (isotonic) +/- 20%, and
 - c. the solution comprises an isotonicity modifier selected from the group
- 10 consisting of: sucrose, trehalose, mannose, ribose, maltose, glucose, lactose, galactose, arabinose, mannitol, sorbitol, inositol, glycerol, xylitol, propylene glycol, polyethylene glycols (PEGs) and polypropylene/ethylene glycol copolymer.
- 15 30. The liquid pharmaceutical formulation according to any of the preceding claims, wherein
- a. the solution has an ionic strength of 1 uM to 50 mM, and
 - b. the solution has a tonicity of 100% (isotonic) +/- 20%, and
 - c. the solution comprises sucrose and/or mannitol.
- 20 31. The liquid pharmaceutical formulation according to any of the preceding claims, wherein
- a. the solution has a pH of pH \geq 7,4, such as pH \geq 7,5, such as pH \geq 7,6, such as pH \geq 7,7, such as pH \geq 7,8, such as pH \geq 7,9, such as pH \geq 8,0, and
 - b. the solution has an ionic strength of 1 uM to 50 mM, and
 - c. the solution has a tonicity of 100% (isotonic) +/- 20%, and
 - d. the solution comprises an isotonicity modifier selected from the group
- 25 consisting of: sucrose, trehalose, mannose, ribose, maltose, glucose, lactose, galactose, arabinose, mannitol, sorbitol, inositol, glycerol, xylitol, propylene glycol, polyethylene glycols (PEGs) and polypropylene/ethylene glycol copolymer.
- 30 32. The liquid pharmaceutical formulation according to any of the preceding claims, wherein
- 35

- 5
- a. the solution has a pH of $\text{pH} \geq 7,4$, such as $\text{pH} \geq 7,5$, such as $\text{pH} \geq 7,6$, such as $\text{pH} \geq 7,7$, such as $\text{pH} \geq 7,8$, such as $\text{pH} \geq 7,9$, such as $\text{pH} \geq 8,0$, and
 - b. the solution has an ionic strength of 1 μM to 50 mM , and
 - c. the solution has a tonicity of 100% (isotonic) \pm 20%, and
 - d. the solution comprises sucrose and/or mannitol.
- 10
33. The liquid pharmaceutical formulation according to any of the preceding claims, wherein
- a. the solution has a pH of $\text{pH} \geq 8,0$, and
 - b. the solution has an ionic strength of 1 μM to 50 mM , and
 - c. the solution has a tonicity of 100% (isotonic) \pm 20%, and
 - d. the solution comprises an isotonicity modifier selected from the group consisting of: sucrose, trehalose, mannose, ribose, maltose, glucose, lactose, galactose, arabinose, mannitol, sorbitol, inositol, glycerol, xylitol, propylene glycol, polyethylene glycols (PEGs) and polypropylene/ethylene glycol copolymer.
- 15
- 20
34. The liquid pharmaceutical formulation according to any of the preceding claims, wherein
- a. the solution has a pH of $\text{pH} \geq 8,0$, and
 - b. the solution has an ionic strength of 1 μM to 50 mM , and
 - c. the solution has a tonicity of 100% (isotonic) \pm 20%, and
 - d. the solution comprises sucrose and/or mannitol.
- 25
35. The liquid pharmaceutical formulation according to any of the preceding claims further comprising one or more buffers.
- 30
36. The liquid pharmaceutical formulation according to any of the preceding claims, further comprising one or more buffers selected from the group consisting of an acetate buffer, TRIS, amine-containing buffers, amino-acid based buffers such as lysine, hydroxy-lysine, histidine and glycyl-glycine, non-phosphate buffers, bicarbonate buffers, Polysorbate-80 (e.g. Tween 80), HEPES and borate.
- 35

37. The liquid pharmaceutical formulation according to any of the preceding claims, further comprising glycyl-glycine and/or Tween20.
- 5 38. The liquid pharmaceutical formulation according to any of the preceding claims, further comprising glycyl-glycine and Tween20, such as comprising 1 to 20 mM glycyl-glycine and 0,001 to 0,1% Tween20, such as comprising 10 mM glycyl-glycine and 0,01% Tween20.
- 10 39. The liquid pharmaceutical formulation according to any of the preceding claims, comprising approx. 4% mannitol, approx. 1% sucrose, approx. 10 mM glycylglycine, approx. 0,01% polysorbate80, at a pH of approx 8,3.
- 15 40. The liquid pharmaceutical formulation according to any of the preceding claims, further comprising histidine.
41. The liquid pharmaceutical formulation according to any of the preceding claims, further comprising 1-100 mM histidine.
- 20 42. The liquid pharmaceutical formulation according to any of the preceding claims, wherein said variant of any one of SEQ ID NOs:4-9 comprises 1 to 6 individual amino acid substitutions, such as 1 amino acid substitution, such as 2 amino acid substitutions, such as 3 amino acid substitutions, such as 4 amino acid substitutions, such as 5 amino acid substitutions, such as 6 individual amino acid substitutions.
- 25 43. The liquid pharmaceutical formulation according to any of the preceding claims, wherein said Annexin A1 N-terminal-peptide is
AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV-NH₂
(SED ID NO:8; Annexin A1 2-48 V24L), or variant thereof comprising 1 to 6
30 individual amino acid substitutions, such as 1 amino acid substitution, such as 2 amino acid substitutions, such as 3 amino acid substitutions, such as 4 amino acid substitutions, such as 5 amino acid substitutions, such as 6 individual amino acid substitutions.

44. The liquid pharmaceutical formulation according to any of the preceding claims, wherein said variant of any one of SEQ ID NOs:4-9 comprises 3 individual amino acid substitutions.
- 5 45. The liquid pharmaceutical formulation according to any of the preceding claims, wherein said variant of any one of SEQ ID NOs:4-9 comprises 2 individual amino acid substitutions.
- 10 46. The liquid pharmaceutical formulation according to any of the preceding claims, wherein said variant of any one of SEQ ID NOs:4-9 comprises 1 amino acid substitution.
- 15 47. The liquid pharmaceutical formulation according to any of the preceding claims, wherein said Annexin A1 N-terminal-peptide is C-terminally amidated.
48. The liquid pharmaceutical formulation according to any of the preceding claims, wherein said Annexin A1 N-terminal-peptide is
AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV-NH₂
(SEQ ID NO:8; Annexin A1 2-48 V24L), optionally C-terminally amidated.
- 20 49. A process of preparing a liquid pharmaceutical formulation according to any of the preceding claims, comprising the steps of
- a. mixing an Annexin A1 N-terminal-peptide with a solvent according to any of the preceding items,
 - 25 b. optionally filtering the mixture of step a., and
 - c. adjusting the pH of said liquid pharmaceutical formulation.
50. A process of preparing a lyophilized pharmaceutical formulation, said process comprising the steps of
- 30 a. providing the liquid pharmaceutical formulation according to any of the preceding claims, and
 - b. lyophilizing said liquid of step a.
- 35 51. A lyophilized pharmaceutical formulation obtained by the process according to claim 50.

52. A method of making a reconstituted solution comprising an Annexin A1 N-terminal-peptide, said method comprising
- 5 a. providing a lyophilized pharmaceutical formulation according to any one of claims 50-51, and
- b. dissolving said lyophilized pharmaceutical formulation in a solvent.
53. A reconstituted solution obtained by the method according to claim 52.
- 10 54. The liquid pharmaceutical formulation or the lyophilized pharmaceutical formulation or the reconstituted solution according to any of the preceding claims for use as a medicament.
- 15 55. The liquid pharmaceutical formulation or the lyophilized pharmaceutical formulation or the reconstituted solution according to any of the preceding claims for use in the treatment of an ischemic condition and/or an inflammatory condition.




Fig. 1



Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7

AxnA1 purity after 3 month at 40°C




Fig. 8




Fig. 9




Fig. 10




Fig. 11